phbi_10q.htm

0001477932-23-000992.txt : 20230214 0001477932-23-000992.hdr.sgml : 20230214 20230214151908 ACCESSION NUMBER: 0001477932-23-000992 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharmagreen Biotech Inc. CENTRAL INDEX KEY: 0001435181 STANDARD INDUSTRIAL CLASSIFICATION: AIRPORTS, FLYING FIELDS & AIRPORT TERMINAL SERVICES [4581] IRS NUMBER: 980491567 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56090 FILM NUMBER: 23627834 BUSINESS ADDRESS: STREET 1: 2987 BLACKBEAR COURT CITY: COQUITLAM STATE: A1 ZIP: V3E3A2 BUSINESS PHONE: 702-803-9404 MAIL ADDRESS: STREET 1: 2987 BLACKBEAR COURT CITY: COQUITLAM STATE: A1 ZIP: V3E3A2 FORMER COMPANY: FORMER CONFORMED NAME: Air Transport Group Holdings, Inc. DATE OF NAME CHANGE: 20081106 FORMER COMPANY: FORMER CONFORMED NAME: Azure International, Inc. DATE OF NAME CHANGE: 20080515 10-Q 1 phbi_10q.htm FORM 10-Q phbi_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2022

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

000-56090

(Commission File Number)

PHARMAGREEN BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada

92-1737808

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

2987 Blackbear Court, Coquitlam, British Columbia		V3E 3A2
(Address of principal executive offices)		(Zip Code)

702-803-9404

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to section 12(g) of the Act: Common Stock

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☐ Yes ☒ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Non-accelerated filer	☒
Accelerated filer	☐	Smaller reporting company	☒
		Emerging Growth	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of February 14, 2023, we had 454,760,969 shares of common stock issued and outstanding.

TABLE of CONTENTS

PART I—FINANCIAL INFORMATION		4

Item 1.	Financial Statements.	4

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	18

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	21

Item 4.	Controls and Procedures.	21

PART II—OTHER INFORMATION		22

Item 1.	Legal Proceedings.	22

Item 1A.	Risk Factors.	22

Item 2.	Unregistered Sales of Securities and Use of Proceeds.	22

Item 3.	Defaults Upon Senior Securities.	23

Item 4.	Mine Safety Disclosure.	23

Item 5.	Other Information.	23

Item 6.	Exhibits.	23

SIGNATURES		25

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Financial Statements

For the Three Months Ended December 31, 2022

(Expressed in U.S. Dollars)

(Unaudited)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Balance Sheets

(Expressed in U.S. dollars)

	December 31, 2022			September 30, 2022
	$			$
	(Unaudited)
Assets

Current assets

Cash		24,964			8,016
Amounts receivable		465			383
Prepaid expenses and deposits (Notes 11 and 12)		186,239			200,572

Total assets		211,668			208,971

Liabilities and Stockholders’ Deficit

Current liabilities

Accounts payable and accrued liabilities (Notes 3 and 7)		783,212			724,876
Advances from Alliance Growers Corp. (Note 12(a))		55,342			54,847
Loans payable (Note 4)		128,593			99,077
Convertible notes – current portion, net of unamortized discount of $9,859 and $15,780, respectively (Note 5)		175,959			120,038
Derivative liabilities (Notes 5 and 6)		110,443			271,394
Due to related parties (Note 7)		665,293			641,915

Total current liabilities		1,918,842			1,912,147

Loans payable (Note 4)		-			29,252
Loans payable to related parties (Note 7)		90,584			90,221

Total liabilities		2,009,426			2,031,620

Stockholders’ deficit

Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 shares issued and outstanding (Note 9)		10			10
Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 454,760,969 and 442,260,969 shares issued and outstanding, respectively (Note 8)		454,761			442,261
Common stock issuable		-			1,130
Additional paid-in capital (Note 8)		10,326,777			10,261,777
Accumulated other comprehensive income		81,648			93,753
Deficit		(12,614,269	)		(12,574,895	)

Total Pharmagreen Biotech Inc. stockholders’ deficit		(1,751,073	)		(1,775,964	)

Non-controlling interest		(46,685	)		(46,685	)

Total stockholders’ deficit		(1,797,758	)		(1,822,649	)

Total liabilities and stockholders’ deficit		211,668			208,971

Nature of business and continuance of operations (Note 1)
Commitments and contingencies (Note 12)
Subsequent events (Note 13)

(The accompanying notes are an integral part of these unaudited condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Expressed in U.S. dollars)

(Unaudited)

	Three months ended December 31, 2022 $			Three months ended December 31, 2021 $

Expenses

Consulting fees (Note 7 and 12)		139,905			139,528
Foreign exchange (gain) loss		(2,847	)		576
General and administrative		17,756			27,213
Professional fees		24,472			31,459
Salaries and wages		1,807			4,884

Total expenses		181,093			203,660

Net loss before other income (expenses)		(181,093	)		(203,660	)

Other income (expense)

Accretion of discount on convertible notes (Note 5)		(10,921	)		(1,799	)
Interest and finance costs (Note 4 and 5)		(8,311	)		(10,091	)
Gain on change in fair value of derivative liabilities (Note 6)		160,951			234,274

Total other income		141,719			222,384

Net (loss) income		(39,374	)		18,724

Less: net loss attributable to non-controlling interest		-			-

Net (loss) income attributable to Pharmagreen Biotech Inc.		(39,374	)		18,724

Comprehensive income (loss)

Foreign currency translation loss		(12,105	)		(2,463	)

Comprehensive (loss) income attributable to Pharmagreen Biotech Inc.		(51,479	)		16,261

Basic and diluted (loss) income per share attributable to Pharmagreen Biotech Inc. stockholders		(0.00	)		0.00

Weighted average number of shares outstanding used in the calculation of net (loss) income per share attributable to Pharmagreen Biotech Inc.		446,527,273			384,214,747

(The accompanying notes are an integral part of these unaudited condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit

(Expressed in U.S. dollars)

(Unaudited)

	Preferred stock				Common stock				Common stock			Additional paid-in		Accumulated other comprehensive income						Non -controlling			Total stockholders’
	Number of shares		Amount $		Number of shares		Amount $		issuable $			capital $		(loss) $			Deficit $			interest $			deficit $

Balance, September 30, 2021		10,000		10		381,171,269		381,171		-			9,680,572		(8,378	)		(11,699,417	)		(46,658	)		(1,692,700	)

Issuance of units for cash		-		-		4,000,000		4,000		-			88,000		-			-			-			92,000

Foreign currency translation loss		-		-		-		-		-			-		(2,463	)		-			-			(2,463	)

Net income for the period		-		-		-		-		-			-		-			18,724			-			18,724

Balance, December 31, 2021		10,000		10		385,171,269		385,171		-			9,768,572		(10,841	)		(11,680,693	)		(46,658	)		(1,584,439	)

Balance, September 30, 2022		10,000		10		442,260,969		442,261		1,130			10,261,777		93,753			(12,574,895	)		(46,685	)		(1,822,649	)

Issuance of common stock for services		-		-		12,500,000		12,500		(1,130	)		65,000		-			-			-			76,370

Foreign currency translation loss		-		-		-		-		-			-		(12,105	)		-			-			(12,105	)

Net loss for the period		-		-		-		-		-			-		-			(39,374	)		-			(39,374	)

Balance, December 31, 2022		10,000		10		454,760,969		454,761		-			10,326,777		81,648			(12,614,269	)		(46,685	)		(1,797,758	)

(The accompanying notes are an integral part of these unaudited condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

(Unaudited)

	Three months ended December 31, 2022			Three months ended December 31, 2021
	$			$
OPERATING ACTIVITIES

Net (loss) income		(39,374	)		18,724

Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on convertible notes		10,921			1,799
Gain on change in fair value of derivative liabilities		(160,951	)		(234,274	)
Common stock issued or issuable for services		76,370			-

Changes in non-cash operating assets and liabilities:
Accounts receivable		(82	)		228
Prepaid expenses and deposits		14,333			274
Accounts payable and accrued liabilities		53,336			40,017
Due to related parties		25,948			24,702

Net cash used in operating activities		(19,499	)		(148,530	)

FINANCING ACTIVITIES

Proceeds from issuance of convertible note		50,000			-
Proceeds from issuance of shares		-			92,000
Proceeds from loans from related party		-			50,000
Repayment of loans from related parties		(2,570	)		(6,041	)

Net cash provided by financing activities		47,430			135,959

Effect of foreign exchange rate changes on cash		(10,983	)		(2,255	)

Change in cash		16,948			(14,826	)

Cash, beginning of period		8,016			25,300

Cash, end of period		24,964			10,474

Supplemental disclosures:

Interest paid		-			-
Income taxes paid		-			-

(The accompanying notes are an integral part of these unaudited condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

Nature of Business and Continuance of Operations

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc. On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the Secretary of State of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc. The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the production of starter plantlets for the North American high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties.

Going Concern

These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at December 31, 2022, the Company has not earned any revenues from operations, has a working capital deficit of $1,707,174, and has an accumulated deficit of $12,614,269. During the three months ended December 31, 2022, the Company incurred a net loss of $39,374 and used cash flows for operations of $19,499. Furthermore, the Company has defaulted on other convertible notes. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. Specifically, the Company attributes the pandemic to a delay in a planned financing which was to be used for the construction of the biotech complex, resulting in an impairment of the capitalized construction-in-progress at September 30, 2020. The extent to which the COVID-19 pandemic further impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources, and financial results.

2. Significant Accounting Policies

	(a)	Interim Financial Statements
		These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

Significant Accounting Policies (continued)

	(b)	Basis of Presentation
		The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

	(c)	Use of Estimates and Judgments
		The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to 12 months from the end of the reporting period.

	(d)	Recently Adopted Accounting Pronouncements
		The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consists of the following:

	December 31, 2022 $		September 30, 2022 $

Accounts payable		684,679		644,970
Accrued interest payable		98,533		79,906

		783,212		724,876

4.	Loans Payable

(a)

On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement. The promissory note is unsecured, was due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. At December 31, 2022, the Company has recorded accrued interest payable of $12,415 (September 30, 2022 - $11,408) and the promissory note is in default. Refer to Note 12(b).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

4.	Loans Payable (continued)

(b)

On April 22, 2020, the Company received a loan for Cdn$40,000 from the Government of Canada under the Canada Emergency Business Account program (“CEBA”). As at December 31, 2022, the balance owing is $29,516 (Cdn$40,000) (September 30, 2022 - $29,252 (Cdn$40,000)). These funds are interest free until December 31, 2023, at which time the remaining balance will convert to a 2-year term loan at an interest rate of 5% per annum. If the Company repays the loan prior to December 31, 2023, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000.

(c)

On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid for financing costs, resulting in net proceeds to the Company of $75,000. The note was due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. On August 2, 2022, the lender was ordered to surrender all common stock of the Company for cancellation, and surrender conversion rights for all remaining convertible notes pursuant to a judgement filed by the Securities and Exchange Commission with the United States District Court, Southern District of New York against the lender. As a result, the Company received and cancelled 660,300 shares of common stock and the conversion rights embedded in the convertible note was relinquished. As a result, the convertible note of $59,077 was reclassified from a convertible note payable to loans payable and its derivative liability of $163,760 was derecognized. In addition, the derecognition of the default penalty of $53,007 that was previously recognized and the fair value of the 660,300 shares of common stock of $4,606 were recognized as a recovery of default penalties during the year ended September 30, 2022.

As at December 31, 2022, the principal balance owing is $59,077 (September 30, 2022 - $59,077) and the Company has recorded interest payable of $25,447 (September 30, 2022 - $23,664).

Convertible Notes

(a)

On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the commitment date, and the convertible notes contained a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $32,485 as additional paid-in capital and reduced the carrying value of the convertible note to $nil. The carrying value will be accreted over the term of the convertible notes up to their face value of $32,485.

As of December 31, 2022, the carrying value of the convertible notes was $21,885 (September 30, 2022 - $17,799) and had an unamortized discount of $5,183 (September 30, 2022 - $9,269). During the three months ended December 31, 2022, the Company recorded accretion expense of $4,086 (2021 - $1,799).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

Convertible Notes (continued)

	(b)	On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note was due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity.

		As at December 31, 2022, the carrying value of the convertible note was $78,750 (September 30, 2022 - $78,750) and the fair value of the derivative liability was $104,676 (September 30, 2022 - $260,908).

	(c)	On March 11, 2022, the Company entered into a convertible note with an unrelated party for $30,000, with an advance on January 18, 2022, for the full amount. The note is due on January 18, 2023, and bears interest on the unpaid principal balance at a rate of 10% per annum. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to the closing price on the day of receiving the notice to convert. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $15,011, which reduced the carrying value of the convertible note to $14,989. The carrying value will be accreted over the term of the convertible note up to its face value of $30,000.

		As of December 31, 2022, the carrying value of the convertible notes was $28,742 (September 30, 2022 - $23,489), had an unamortized discount of $1,258 (September 30, 2022 - $6,511), and the fair value of the derivative liability was $5,767 (September 30, 2022 - $10,486). During the three months ended December 31, 2022, the Company recorded accretion expense of $5,253 (2021 - $nil).

	(d)	On November 2, 2022, the Company entered into a secured convertible note with an unrelated party for proceeds of $50,000. The note is due on May 1, 2023 and bears a one-time interest charge of 10% automatically accrued on the issuance date. The one-time interest charge was netted against the convertible note and is being amortized over the term using the effective interest rate method. Stringent pre-payment terms of 25% apply and any amount of principal or interest on the note which is not paid when due shall bear interest at 22% per annum or the highest rate permitted by law.

		The note may be converted at any time after 120 days following the date of issuance into shares of Company’s common stock at a conversion price equal 57.5% of the average of the 3 lowest trading prices during the 15-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging. As the note isn’t convertible until 120 days following issuance, no derivative liability was recognized as of December 31, 2022.

		As of December 31, 2022, the carrying value of the convertible notes was $46,582 (September 30, 2022 - $nil) and had an unamortized discount of $3,418 (September 30, 2022 - $nil). During the three months ended December 31, 2022, the Company recorded accretion expense of $1,582 (2021 - $nil).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

Derivative Liabilities

The embedded conversion option of the Company’s convertible notes described in Note 5 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:

Balance, September 30, 2022	271,394
Change in fair value of embedded conversion option	(160,951	)

Balance, December 31, 2022	110,443

The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using the binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the assumptions used in the calculations:

	Expected volatility			Risk-free interest rate			Expected dividend yield			Expected life (in years)

As at September 30, 2022		161	%		3.33	%		0	%		0.26
As at December 31, 2022		217	%		4.38	%		0	%		0.22

7.	Related Party Transactions

	(a)	As at December 31, 2022, the Company owed $611,057 (Cdn$828,105) (September 30, 2022 - $588,165 (Cdn$804,285)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the three months ended December 31, 2022, the Company incurred consulting fees of $23,491 (2021 - $23,808) to the President of the Company.

	(b)	As at December 31, 2022, the Company owed $54,236 (Cdn$73,500) (September 30, 2022 - $53,750 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.

	(c)	As at December 31, 2022, the Company owed $40,584 (Cdn$55,000) (September 30, 2022 - $40,221 (Cdn$55,000)) to the father of the President of the Company, which bears interest at 10% per annum, is unsecured and due on June 1, 2026. As of December 31, 2022, the Company recognized accrued interest of $2,386 (Cdn$3,233) (September 30, 2022 – $331 (Cdn$452)).

	(d)	As at December 31, 2022, the Company owed $50,000 (September 30, 2022 - $50,000) to the father of the President of the Company, which bears interest at 10% per annum, is unsecured and due on June 1, 2026. As of December 31, 2022, the Company recognized accrued interest of $2,932 (September 30, 2022 - $387).

	(e)	As at December 31, 2022, the Company owed $25,236 (Cdn$34,200) (September 30, 2022 – $25,010 (Cdn$34,200)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.

	(f)	As at December 31, 2022, the Company owed $534,613 (Cdn$724,508) (September 30, 2022 – $509,610 (Cdn$696,866)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the three months ended December 31, 2022, the Company incurred consulting fees of $23,491 (2021 - $23,808) to the company controlled by the Chief Financial Officer of WFS.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

8.	Common Stock

	Three months ended December 31, 2022

	(a)	On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 for management consulting and strategic business advisory services (Note 12(g)).

	(b)	On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 for product endorsement services (Note 12(h)).

	Three months ended December 31, 2021

	(c)	On October 21, 2021, the Company issued 4,000,000 shares of common stock at $0.025 per common stock for proceeds of $100,000. In connection with the financing, the Company incurred commission fees of $8,000.

9.	Preferred Stock
	On October 13, 2020, the Company filed a certificate of amendment to its articles of incorporation, whereby it increased the authorized capital to 2,000,000,000 shares of common stock with a par value of $0.001 per share and 1,000,000 preferred shares with a par value of $0.001. On October 14, 2020, the Company designated 10,000 preferred shares as Series A Super Voting Preferred Stock.
	The Series A Super Voting Preferred Stock has the following rights and restrictions:
	Dividends - Initially, there will be no dividends due or payable on the Series A Super Voting Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.
	Liquidation and Redemption Rights - Upon the occurrence of a Liquidation Event, the holders of Series A Super Voting Preferred Stock are entitled to receive net assets on a pro-rata basis. Each holder of Series A Super Voting Preferred Stock is entitled to receive ratably any dividends declared by the Board, if any, out of funds legally available for the payment of dividends.
	Rank - All shares of the Series A Super Voting Preferred Stock shall rank (i) senior to the Corporation’s (A) Common Stock, par value $0.001 per share ( “Common Stock” ), and any other class or series of capital stock of the Corporation hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Section 4, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Super Voting Preferred-Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.
	Voting Rights - If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.
	Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

	·	[twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A, Series A and any newly designated Preferred stock issued and outstanding at the time of voting}] Divided by:

	·	[the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

9.	Preferred Stock(continued)

Protective Provisions So long as any shares of Series A Super Voting Preferred Stock are outstanding, the Corporation shall not, without first obtaining the unanimous written consent of the holders of Series A Super Voting Preferred Stock, alter or change the rights, preferences or privileges of the Series A Super Voting Preferred so as to affect adversely the holders of Series A Super Voting Preferred Stock.

On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a Director of the Company for proceeds of $10. In connection with the issuance of the Series A Super Voting Preferred Stock, the Company evaluated whether the preferred stock should be classified as a liability based on the guidance under ASC 480, Distinguishing Liabilities from Equity. The Series A Super Voting Preferred Stock are not considered mandatorily redeemable, are not settleable in a variable number of shares, and do not contain any features embedded that required a separate assessment. As a result, the Company determined the Series A Super Voting Preferred Stock were not a liability and classified the preferred stock within equity in the amount of the aggregate par value of the issued shares of preferred stock, with any excess attributed to additional paid-in capital.

10.

Share Purchase Warrants

The following table summarizes the continuity of the Company’s share purchase warrants:

	Number of warrants			Weighted average exercise price $

Balance, September 30, 2022		58,722,500			0.05

Expired		(5,400,000	)		0.05

Balance, December 31, 2022		53,322,500			0.05

As at December 31, 2022, the following share purchase warrants were outstanding:

Number of warrants		Exercise price		Expiry date

	300,000	$	0.05	January 6, 2023
	2,000,000	$	0.05	January 7, 2023
	2,000,000	$	0.05	January 18, 2023
	300,000	$	0.05	January 25, 2023
	6,000.000	$	0.05	January 27, 2023
	3,400,000	$	0.05	January 28, 2023
	2,800,000	$	0.05	January 30, 2023
	872,500	$	0.05	February 13, 2023
	350,000	$	0.05	February 20, 2023
	2,500,000	$	0.05	April 5, 2023
	600,000	$	0.05	April 7, 2023
	1,000,000	$	0.05	April 12, 2023
	2,250,000	$	0.05	April 15, 2023
	5,100,000	$	0.05	July 1, 2023
	500,000	$	0.05	July 19, 2023
	500,000	$	0.05	July 24, 2023
	2,000,000	$	0.05	September 15, 2023
	650,000	$	0.05	January 19, 2024
	4,800,000	$	0.05	May 19, 2024
	2,400,000	$	0.05	May 20, 2024
	10,000,000	$	0.05	May 26, 2024
	2,000,000	$	0.05	May 27, 2024
	1,000,000	$	0.05	May 30, 2024

	53,322,500

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

11.

Memorandum of Understanding

On July 25, 2021 the Company entered into a Memorandum of Understanding (“MOU”) to acquire all the assets and cannabis business operation, including 12 acres of property, structure and cannabis licenses, existing sales channels and distribution networks, from a private company situated in Northern California. Upon reaching a definitive agreement, the Company intends to further develop a state- of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and Regional County. The acquisition price is $2,400,000 to be paid through a combination of cash and shares. The Company also has an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. As at December 31, 2022, the Company has advanced $88,850 (September 30, 2022 - $88,850) under the MOU, which will be applied against the final purchase price upon completion of a definitive agreement. This amount has been included in prepaid expenses and deposits. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction. Thus, there is no assurance that the Company will ever enter into, and consummate, a definitive agreement with respect to the contemplated transaction.

Subsequent to the three months ended December 31, 2022, the Company terminated the MOU. The advance of $88,850 was converted into a note bearing no interest until September 30, 2025.

12.

Commitments and Contingencies

(a)

Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at December 31, 2022, the Company received advances of $55,342 (Cdn$75,000) (September 30, 2022 - $54,847 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand.

(b)

On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 4(a)). In addition, the Company is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.

On March 10, 2021, the noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court. On September 23, 2021, the noteholder filed a new Notice of Motion for Summary Judgement in Lieu of Complaint with the State of New York Supreme Court, County of New York for $44,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. The plaintiff filed for an oral argument which was heard by the State of New York Supreme Court on September 15, 2022 and is pending a final decision. The Company believes that the claim has no merit and intends to defend its position vigorously.

(c)

Effective May 14, 2021, the Company entered into a Software as a Service Agreement with Novation Solutions Inc. (“DealMaker”) to effect the Company’s planned Regulation A offering, including the set-up of an automated tracking, signing, and reconciliation portal. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 30 days prior to launching the portal, and a post launch monthly fee of $1,000. The monthly fee will automatically renew each month for the shorter of the duration of the offering period, or one year.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

December 31, 2022

(Expressed in U.S. dollars)

(Unaudited)

12.

Commitments and Contingencies (continued)

	(d)	On May 2, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 7,000,000 shares of common stock in exchange for market awareness services. On May 3, 2022, the Company issued 7,000,000 shares of common stock with a fair value of $84,700 pursuant to the agreement. As at December 31, 2022, the Company recognized $nil (September 30, 2022 - $15,191) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $15,191 (2021 - $nil) pursuant to the agreement.

	(e)	On May 20, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,000,000 shares of common stock in exchange for public relations and communications services. If both parties agree to continue the agreement for another 6 months, the Company will issue common stock of the Company with a fair value of $80,000. On August 22, 2022, the Company issued 9,000,000 shares of common stock with a fair value of $81,000 pursuant to the agreement. As at December 31, 2022, the Company recognized $nil (September 30, 2022 - $21,481) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $21,481 (2021 - $nil) pursuant to the agreement.

	(f)	On September 8, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,500,000 shares of common stock in exchange for corporate development, investor, media, public relations, and marketing services. On September 13, 2022, the Company issued 9,500,000 shares of common stock with a fair value of $85,500 pursuant to the agreement. As at December 31, 2022, the Company recognized $31,072 (September 30, 2022 - $75,050) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $43,978 (2021 - $nil) pursuant to the agreement.

	(g)	On September 15, 2022, the Company entered into a consulting agreement with a twelve-month term. Pursuant to the agreement, the Company agreed to issue 2,500,000 shares of common stock in exchange for management consulting and strategic business advisory services. On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 pursuant to the agreement (Note 8(a)). As at December 31, 2022, the Company recognized $19,419 (September 30, 2022 - $nil) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $6,951 (2021 - $nil) pursuant to the agreement.

	(h)	On November 28, 2022, the Company entered into a product endorsement agreement with Tyrell Crosby for an eighteen-month term. Pursuant to the agreement, the Company agreed to issue 10,000,000 shares of common stock in exchange for product endorsement services. On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 pursuant to the agreement (Note 8(b)). As at December 31, 2022, the Company recognized $46,898 (September 30, 2022 - $nil) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $3,102 (2021 - $nil) pursuant to the agreement.

13.	Subsequent Events

	(a)	Subsequent to the three months ended December 31, 2022, the Company terminated the MOU described in Note 11. The advance of $88,850 was converted into a note bearing no interest until September 30, 2025.

	(b)	Subsequent to the three months ended December 31, 2022, a total of 17,672,500 share purchase warrants with an exercise price of $0.05 per share expired unexercised.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This section of the Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Company History Overview

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of Nevada, U.S. on November 26, 2007 under the name Azure International, Inc. On October 30, 2008 and effective as of the same date, the Company filed Articles of Merger with the Secretary of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation incorporated on October 16, 2008, and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.

On April 12, 2018, the Company entered into a share exchange agreement with WFS Pharmagreen Inc., a private company incorporated under the laws of British Columbia, Canada, whereby the Company acquired all of the issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company. Upon completion of this transaction, the shareholders of WFS Pharmagreen hold 95.5% of voting control of the Company.

Immediately prior to closing of the Agreement, the majority shareholder of the Company was also the majority shareholder of WFS. As a result of the common ownership upon closing of the transaction, the acquisition was considered a common-control transaction and was outside the scope of the business combination guidance in ASC 805-50. The entities are deemed to be under common control as of February 27, 2018, which was the date that the majority shareholder acquired control of the Company and, therefore, held control over both companies. On May 2, 2018, the Share Exchange Agreement was effected. In connection with this transaction, the Company changed its name on May 8, 2018 to Pharmagreen Biotech Inc. and changed its year end from April 30th to September 30th.

Our principal executive offices are temporarily located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada. Our telephone number is (702-803-9404). Our internet address is www.pharmagreen.ca.

On August 7, 2020, our company (including subsidiaries) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada, Case No. 20-13886.

We expect to continue to incur losses for at least the next 12 months. We do not expect to generate revenue that is sufficient to cover our expenses, and we do not have sufficient cash and cash equivalents to execute our plan of operations for at least the next twelve months. We will need to obtain additional financing, through equity security sales, debt instruments and private financing, to conduct our day-to-day operations, and to fully execute our business plan. We plan to raise the capital necessary to fund our business through the sale of equity securities, debt instruments or private financing. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. This report does not reflect all the adjustments that may be necessary if the Company is unable to continue as a going concern.

Table of Contents

Our Current Business

Pharmagreen Biotech Inc. (the “Company”) was incorporated under the laws of the State of Nevada on November 26, 2007. The Company is headquartered in Coquitlam, British Columbia. The Company’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. However, if the Company is unable to raise additional capital in the near future, due to the Company’s liquidity problems, management expects that the Company will need to curtail operations, liquidate assets, seek additional capital on less favourable terms and/or pursue other remedial measures. These consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

In 2021, the Company had changed its business development from Canada to the United States, as it was determined that the opportunities in the hemp and cannabis industries were much greater in the United States, specifically California.

On July 25, 2021, the Company entered into a Memorandum of Understanding (“MOU”) to acquire all the assets and cannabis business operations (includes 12 acres property, structure and cannabis licenses, existing sales channels and distribution networks) from a private company situated in Northern California. Upon reaching a definitive agreement, the Company intended to further develop a state-of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and Regional County. The acquisition price of $2.4 million was to be paid through a combination of cash and shares. The Company also had an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction.

In 2022, the Cannabis market in California entered a regression stage with prices for the raw materials dropping below production costs including greatly diminished demand for the sun grown raw material. Because of the current state of the Cannabis market in California, the Company terminated the MOU subsequent to the three months ended December 31, 2022. The Company will revisit the developemnt of the biotech complex infrastructure that will be capable of producing tissue cultured high CBD hemp starter plantlets, once the economy turns around.

Focusing on immediate revenues, the Company has been and is currently formulating its nutraceutical products from blends of therapeutic plants and fungi. Utilizing the Company’s expertise in plant genetics, Pharmagreen’s transgenic program uses the newest technology available to research and create nutraceuticals, for daily supplements with the potential to help, support and improve human lives, and to address a wide variety of ailments.

Pharmagreen's first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six medicinal plants to help support the human mind and body. This supplement is produced in a U.S.A cGMP facility, in enteric capsules to enhance the bioavailability of the MaxGenomic(TM) supplement.

Table of Contents

Capital Resources and Liquidity

Our auditors have issued a “going concern” opinion on its audited financial statements for the latest year ended September 30, 2022, meaning that there is substantial doubt if we can continue as an on-going business unless we obtain additional capital. No substantial revenues from our planned business model are anticipated until we have completed financing the Company. As at December 31, 2022, the Company has a working capital deficit of $1,707,174 and an accumulated deficit of $12,614,269. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

We need to seek capital from resources such as the sale of private placements in the Company’s common stock or debt financing, which may not even be available to the Company. However, if such financing were available, because we are a, early-stage company with no or limited operations to date, it would likely have to pay additional costs associated with such financing and in the case of high risk loans be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such financing. If the Company cannot raise additional proceeds via such financing, it may be required to cease business operations.

As of December 31, 2022, we had $24,964 in cash, amounts receivable of $465, and prepaid expenses and deposits of $186,239, as compared to $8,016 in cash, amounts receivable of $383 and prepaid expenses and deposits of $200,572 as of September 30, 2022. As of the date of this Form 10-Q, the current funds available to the Company will not be sufficient to fund the expenses related to maintaining our planned operations. We are in the process of seeking additional equity financing in the form of private placements, loans and registration statements to fund our intended business operations.

Management believes that if subsequent private placements are successful or we are successful in raising funds from registered securities, we will generate sales revenue within twelve months thereof. However, additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.

We do not anticipate researching any further products nor the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees.

Results of Operations

Three Months Ended December 31, 2022

We had no revenue for the three months ended December 31, 2022 and 2021.

Operating expenses in the three months ended December 31, 2022 were $181,093 which was consistent with operating expenses for the three months ended December 31, 2021 of $203,660.

We had a comprehensive loss of $39,374 during the three months ended December 31, 2022, compared to a comprehensive income of $18,724 during the three months ended December 31, 2021. The increase in comprehensive loss in 2022 was mainly attributable to a change in fair value of derivative liabilities from a gain of $234,274 in 2021 to a gain of $160,951 in 2022, which resulted from fluctuations of the derivative liability due to the floating rates attached to the conversion rights to the convertible debt.

During the three months ended December 31, 2022 and 2021, we recognized net loss of $39,374 and a net income of $18,724, respectively.

Table of Contents

Off-balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s principal executive officer and principal financial officer. Based upon that evaluation, our company’s principal executive officer and principal financial officer concluded that as of December 31, 2022 our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting.

The matters involving internal controls and procedures that the Company’s management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee and lack of a majority of outside directors on the Company's board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives; (3) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements; and (4) ineffective controls over period end financial disclosure and reporting processes. Due to these material weaknesses management concluded that our internal control over financial reporting was not effective as of September 30, 2022.

Management believes that the material weaknesses set forth in items (2), (3) and (4) above did not have an effect on the Company's previous reported financial results. However, management believes that the lack of a functioning audit committee and lack of a majority of outside directors on the Company's board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures can result in the Company's determination to its financial statements for the future periods.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Sadler Gibb & Associates LLC, our independent auditors, are not required to and have not performed an assessment of our internal controls over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

On July 22, 2020, the Company received a preliminary statement of claim from a convertible note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the plaintiff has requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal amount of $78,000 for a total sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note.

On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection. The lifting of the stay order further allowed the convertible note holders to convert thereby increasing the number of shares issued and outstanding.

On October 29, 2020 a second note holder filed a statement of claim. This lender, as of December 24, 2020, has completely converted the full amount of the note of $100,000, interest of $8,690 and penalty and fees aggregating $19,500.

Also, as mentioned above, the Company filed voluntary petitions for reorganization under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. The Company’s filing with the Court was designated as Case No. 20-13886. During the pendency of this matter, the Company has also filed motions with the Court seeking authorization to continue to operate its businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. Due to the stay order mentioned, the Company did not file a plan of reorganization with the Court for approval.

On March 12, 2021, the Company entered into a settlement agreement with the convertible noteholder that had filed a preliminary statement of claim on July 22, 2020. Pursuant to the agreement the Company was required to honor various conversion notices and the note holder agreed to wave all principal, interest and penalties incurred.

On March 10, 2021, the promissory note holder referred to in Note 4 (a) of the accompanying consolidated financial statements filed a Notice of Motion For Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court. On October 20, 2021, the promissory note holder filed an Amended Notice of Motion for Summary Judgment in Lieu of Complaint with the State of New York Supreme Court, County of New York for $44,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs and attorney fees. The plaintiff filed for an oral argument which was heard by the State of New York Supreme Court on September 15, 2022 and is pending a final decision. The Company believes the claim is without merit, as evidenced by the initial claim being dismissed by the same courts, and will vigorously defend its position.

Except as mentioned in the preceding paragraphs, there are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or stockholder is a party adverse to the Company or has a material interest adverse to the Company.

Table of Contents

Item 1A. Risk Factors.

As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

The commencement of the Chapter 11 Cases discussed above constituted an event of default under certain of the Company’s debt instruments, including various convertible notes, which resulted in automatic acceleration of the Company’s obligations under such debt instruments. Any efforts to enforce payment obligations under the aforementioned debt instruments are automatically stayed as a result of the filing of the Chapter 11 Cases and the creditors’ rights of enforcement in respect of the debt instruments are subject to the applicable provisions of the Bankruptcy Code.

Item 4. Mine Safety Disclosure.

N/A

Item 5. Other Information.

None

Table of Contents

Item 6. Exhibits.

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

Exhibit Number		Description

(3)		Articles of Incorporation; and (ii) Bylaws

3.1		Articles of Incorporation and Bylaws dated November 26, 2007, as previously filed with the SEC on March 20, 2019.

3.2		Articles of Merger dated, October 30, 2008 (Azure International, Inc./ Air Transport Group Holding, Inc. as previously filed with the SEC on March 20, 2019.

3.3		Securities Exchange Agreement dated April 12, 2018, by and among Air Transport Group Holdings Inc. and WFS Pharmagreen Inc., as previously filed with the SEC on March 20, 2019.

3.4		Articles of Incorporation and Bylaws dated December 19, 2013 for WFS Pharmagreen Inc. as previously filed with the SEC on March 20, 2019.

3.5		Articles of Incorporation and Bylaws dated March 2, 2018 for BC1155097 as previously filed with the SEC on March 20, 2019.

3.6		Articles of Incorporation and Bylaws dated August 2, 2018 for BC1174505 as previously filed with the SEC on March 20, 2019.

(10)		Material Contracts

10.1		Option Agreement with Alliance Growers January 25, 2019 as previously filed with the SEC on March 20, 2019.

10.2		Equity Purchase Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019.

10.3		Registration Rights Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019.

Table of Contents

(31)		Rule 13a-14(a)/15d-14(a) Certifications

31.1		Certification of Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of the Securities Exchange Act of 1934.

31.2		Certification of Principle Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.*

(32)		Section 1350 Certifications

32.1		Certification of Chief Executive Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Principle Financial Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document).

101.SCH		Inline XBRL Taxonomy Extension Schema Document.

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

* Included in Exhibit 31.1

** Included in Exhibit 32.1

Table of Contents

SIGNATURES*

Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Pharmagreen Biotech Inc.

Dated February 14, 2023	By:	/s/ Peter Wojcik
		Peter Wojcik
		President and Director Principal Executive Officer

	By:	/s/ Terry Kwan
		Terry Kwan
		Principal Accounting Officer

EX-31.1 2 phbi_ex311.htm CERTIFICATION phbi_ex311.htm

EXHIBIT 31.1

CERTIFICATION

Peter Wojcik and Terry Kwan, certify that:

1.

We have reviewed this quarterly report on Form 10-Q of Pharmagreen Biotech Inc. for the quarter ended December 31, 2022;

2.

Based on our knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.

Based on our knowledge, the financial statements, and other financial information included in report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.

We are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

We have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

February 14, 2023

By:

/s/ Peter Wojcik

Peter Wojcik

President and Director

Principal Executive Officer

By:

/s/ Terry Kwan

Terry Kwan

Principal Accounting Officer

EX-32.1 3 phbi_ex321.htm CERTIFICATION phbi_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Pharmagreen Biotech Inc. (the “Company”) for the quarter ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the Report), we, Peter Wojcik, Principal Executive Officer of the Company and Terry Kwan, Principal Accounting Officer of the Company certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects the financial condition and results of operations of the Company.

February 14, 2023

/s/ Peter Wojcik

Peter Wojcik

President and Director

Principal Executive Officer

/s/ Terry Kwan

Terry Kwan

Principal Accounting Officer

EX-101.SCH 4 phbi-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Consolidated Financial Statements link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Consolidated Financial Statements (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Nature of Business and Continuance of Operations link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Loans Payable link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Share Purchase Warrants link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Memorandum of Understanding link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Commitments and Contigency link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Derivative Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Share Purchase Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Nature of Business and Continuance of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Loans Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Convertible Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Derivative Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Share Purchase Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Share Purchase Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Memorandum of Understanding (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - Commitments and Contigency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 phbi-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current Condensed Consolidated Financial Statements Assets Current assets Cash Amounts receivable Prepaid expenses and deposits (Notes 11 and 12) Total assets [Assets] Liabilities and Stockholders' Deficit Current liabilities Accounts payable and accrued liabilities (Notes 3 and 7) Advances from Alliance Growers Corp. (Note 12(a)) Loans payable (Note 4) Convertible notes - current portion, net of unamortized discount of $9,859 and $15,780, respectively (Note 5) Derivative liabilities (Notes 5 and 6) Due to related parties (Note 7) Total current liabilities [Liabilities, Current] Loans payable (Note 4) [Loans Payable] Loans payable to related parties (Note 7) Total liabilities [Liabilities] Stockholders' deficit Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 shares issued and outstanding (Note 9) Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 454,760,969 and 442,260,969 shares issued and outstanding, respectively (Note 8) Common stock issuable Additional paid-in capital (Note 8) Accumulated other comprehensive income Deficit Total Pharmagreen Biotech Inc. stockholders' deficit [Stockholders' Equity Attributable to Parent] Non-controlling interest Total stockholders' deficit [Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest] Total liabilities and stockholders' deficit [Liabilities and Equity] Convertible Notes, Unamortized Discount, Current Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Expenses Consulting fees (Note 7 and 12) Foreign exchange (gain) loss [Foreign Currency Transaction Gain (Loss), before Tax] General and administrative Professional fees Salaries and wages Total expenses [Operating Expenses] Net loss before other income (expenses) [Operating Income (Loss)] Other income (expense) Accretion of discount on convertible notes (Note 5) Interest and finance costs (Note 4 and 5) [Interest and Debt Expense] Gain on change in fair value of derivative liabilities (Note 6) Total other income [Other Nonoperating Income (Expense)] Net (loss) income [Net Income (Loss) Attributable to Parent] Less: net loss attributable to non-controlling interest Net (loss) income attributable to Pharmagreen Biotech Inc. [Income (Loss) Attributable to Parent, before Tax] Comprehensive income (loss) Foreign currency translation loss Comprehensive (loss) income attributable to Pharmagreen Biotech Inc. [Comprehensive Income (Loss), Net of Tax, Attributable to Parent] Basic and diluted (loss) income per share attributable to Pharmagreen Biotech Inc. stockholders Weighted average number of shares outstanding used in the calculation of net (loss) income per share attributable to Pharmagreen Biotech Inc. Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statement [Table] Statement [Line Items] Equity Components [Axis] Common Stock Common Stock [Member] Preferred Stock Preferred Stock [Member] Common Stock Issuable Additional Paid-In Capital Accumulated other comprehensive income (loss) Accumulated Deficit Non-controlling Interest Balance, shares [Shares, Issued] Balance, amount Issuance of units for cash, shares Issuance of units for cash, amount Foreign currency translation loss Net income for the period Issuance of common stock for services, shares Issuance of common stock for services, amount Balance, shares Balance, amount Condensed Consolidated Statements of Cash Flows (Unaudited) OPERATING ACTIVITIES Net (loss) income [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Accretion of discount on convertible notes Gain on change in fair value of derivative liabilities Common stock issued or issuable for services Changes in non-cash operating assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Prepaid expenses and deposits [Increase (Decrease) in Prepaid Expense and Other Assets] Accounts payable and accrued liabilities Due to related parties Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] FINANCING ACTIVITIES Proceeds from issuance of convertible note Proceeds from issuance of shares Proceeds from loans from related party Repayment of loans from related parties [Repayments of Related Party Debt] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Effect of foreign exchange rate changes on cash Change in cash [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect] Cash, beginning of period [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash, end of period Supplemental disclosures: Interest paid Income taxes paid Nature of Business and Continuance of Operations Nature of Business and Continuance of Operations Nature of Operations [Text Block] Significant Accounting Policies Significant Accounting Policies Significant Accounting Policies [Text Block] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Loans Payable Loans Payable [Loans Payable 1] Convertible Notes Convertible Notes Debt Disclosure [Text Block] Derivative Liabilities Derivative Liabilities Derivative Instruments and Hedging Activities Disclosure [Text Block] Related Party Transactions Related Party Transactions Related Party Transactions Disclosure [Text Block] Common Stock Common Stock Stockholders' Equity Note Disclosure [Text Block] Preferred Stock Preferred Stock [Text Block] Share Purchase Warrants Share Purchase Warrants [Share Purchase Warrants] Memorandum of Understanding Memorandum of Understanding [Memorandum of Understanding] Commitments and Contigency Commitments and Contigency Commitments and Contingencies Disclosure [Text Block] Subsequent Events Subsequent Events Subsequent Events [Text Block] Interim Financial Statements Basis of Presentation Use of Estimates and Judgments Recently Adopted Accounting Pronouncements Schedule of Accounts Payable and Accrued Liabilities Schedule of Derivative Liability Schedule of analytical assumptions of derivatives Schedule of Share Purchase Warrants Schedule of Warrants Outstanding Working Capital Deficit Accumulated deficit Net loss Net cash used in operating activities Accounts payable Accrued interest payable Accounts Payable and Accrued Liabilities Statement Class Of Stock Axis EX-101.CAL 6 phbi-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 phbi-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 phbi-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Dec. 31, 2022	Feb. 14, 2023
Cover [Abstract]
Entity Registrant Name	PHARMAGREEN BIOTECH INC.
Entity Central Index Key	0001435181
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		454,760,969
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56090
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	92-1737808
Entity Address Address Line 1	2987 Blackbear Court
Entity Address City Or Town	Coquitlam
Entity Address State Or Province	BC
Entity Address Postal Zip Code	V3E 3A2
City Area Code	702
Local Phone Number	803-9404
Entity Interactive Data Current	No

XML 10 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Current assets
Cash	$ 24,964	$ 8,016
Amounts receivable	465	383
Prepaid expenses and deposits (Notes 11 and 12)	186,239	200,572
Total assets	211,668	208,971
Current liabilities
Accounts payable and accrued liabilities (Notes 3 and 7)	783,212	724,876
Advances from Alliance Growers Corp. (Note 12(a))	55,342	54,847
Loans payable (Note 4)	128,593	99,077
Convertible notes - current portion, net of unamortized discount of $9,859 and $15,780, respectively (Note 5)	175,959	120,038
Derivative liabilities (Notes 5 and 6)	110,443	271,394
Due to related parties (Note 7)	665,293	641,915
Total current liabilities	1,918,842	1,912,147
Loans payable (Note 4)	0	29,252
Loans payable to related parties (Note 7)	90,584	90,221
Total liabilities	2,009,426	2,031,620
Stockholders' deficit
Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 shares issued and outstanding (Note 9)	10	10
Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 454,760,969 and 442,260,969 shares issued and outstanding, respectively (Note 8)	454,761	442,261
Common stock issuable	0	1,130
Additional paid-in capital (Note 8)	10,326,777	10,261,777
Accumulated other comprehensive income	81,648	93,753
Deficit	(12,614,269)	(12,574,895)
Total Pharmagreen Biotech Inc. stockholders' deficit	(1,751,073)	(1,775,964)
Non-controlling interest	(46,685)	(46,685)
Total stockholders' deficit	(1,797,758)	(1,822,649)
Total liabilities and stockholders' deficit	$ 211,668	$ 208,971

XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements (Parenthetical) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Condensed Consolidated Financial Statements
Convertible Notes, Unamortized Discount, Current	$ 9,859	$ 15,780
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	10,000	10,000
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Shares Issued	454,760,969	442,260,969
Common Stock, Shares Outstanding	454,760,969	442,260,969

XML 12 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Expenses
Consulting fees (Note 7 and 12)	$ 139,905	$ 139,528
Foreign exchange (gain) loss	(2,847)	576
General and administrative	17,756	27,213
Professional fees	24,472	31,459
Salaries and wages	1,807	4,884
Total expenses	181,093	203,660
Net loss before other income (expenses)	(181,093)	(203,660)
Other income (expense)
Accretion of discount on convertible notes (Note 5)	(10,921)	(1,799)
Interest and finance costs (Note 4 and 5)	(8,311)	(10,091)
Gain on change in fair value of derivative liabilities (Note 6)	160,951	234,274
Total other income	141,719	222,384
Net (loss) income	(39,374)	18,724
Less: net loss attributable to non-controlling interest	0	0
Net (loss) income attributable to Pharmagreen Biotech Inc.	(39,374)	18,724
Comprehensive income (loss)
Foreign currency translation loss	(12,105)	(2,463)
Comprehensive (loss) income attributable to Pharmagreen Biotech Inc.	$ (51,479)	$ 16,261
Basic and diluted (loss) income per share attributable to Pharmagreen Biotech Inc. stockholders	$ (0.00)	$ 0.00
Weighted average number of shares outstanding used in the calculation of net (loss) income per share attributable to Pharmagreen Biotech Inc.	446,527,273	384,214,747

XML 13 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Total	Common Stock	Preferred Stock	Common Stock Issuable	Additional Paid-In Capital	Accumulated other comprehensive income (loss)	Accumulated Deficit	Non-controlling Interest
Balance, shares at Sep. 30, 2021		381,171,269	10,000
Balance, amount at Sep. 30, 2021	$ (1,692,700)	$ 381,171	$ 10	$ 0	$ 9,680,572	$ (8,378)	$ (11,699,417)	$ (46,658)
Issuance of units for cash, shares		4,000,000
Issuance of units for cash, amount	92,000	$ 4,000	0	0	88,000	0	0	0
Foreign currency translation loss	(2,463)	0	0	0	0	(2,463)	0	0
Net income for the period	18,724	$ 0	$ 0	0	0	0	18,724	0
Balance, shares at Dec. 31, 2021		385,171,269	10,000
Balance, amount at Dec. 31, 2021	(1,584,439)	$ 385,171	$ 10	0	9,768,572	(10,841)	(11,680,693)	(46,658)
Balance, shares at Sep. 30, 2022		442,260,969	10,000
Balance, amount at Sep. 30, 2022	(1,822,649)	$ 442,261	$ 10	1,130	10,261,777	93,753	(12,574,895)	(46,685)
Foreign currency translation loss	(12,105)	0	0	0	0	(12,105)	0	0
Net income for the period	(39,374)	$ 0	0	0	0	0	(39,374)	0
Issuance of common stock for services, shares		12,500,000
Issuance of common stock for services, amount	76,370	$ 12,500	$ 0	(1,130)	65,000	0	0	0
Balance, shares at Dec. 31, 2022		454,760,969	10,000
Balance, amount at Dec. 31, 2022	$ (1,797,758)	$ 454,761	$ 10	$ 0	$ 10,326,777	$ 81,648	$ (12,614,269)	$ (46,685)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
OPERATING ACTIVITIES
Net (loss) income	$ (39,374)	$ 18,724
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on convertible notes	10,921	1,799
Gain on change in fair value of derivative liabilities	(160,951)	(234,274)
Common stock issued or issuable for services	76,370	0
Changes in non-cash operating assets and liabilities:
Accounts receivable	(82)	228
Prepaid expenses and deposits	14,333	274
Accounts payable and accrued liabilities	53,336	40,017
Due to related parties	25,948	24,702
Net cash used in operating activities	(19,499)	(148,530)
FINANCING ACTIVITIES
Proceeds from issuance of convertible note	50,000	0
Proceeds from issuance of shares	0	92,000
Proceeds from loans from related party	0	50,000
Repayment of loans from related parties	(2,570)	(6,041)
Net cash provided by financing activities	47,430	135,959
Effect of foreign exchange rate changes on cash	(10,983)	(2,255)
Change in cash	16,948	(14,826)
Cash, beginning of period	8,016	25,300
Cash, end of period	24,964	10,474
Supplemental disclosures:
Interest paid	0	0
Income taxes paid	$ 0	$ 0

XML 15 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Continuance of Operations

3 Months Ended

Dec. 31, 2022

Nature of Business and Continuance of Operations

Nature of Business and Continuance of Operations

Nature of Business and Continuance of Operations

Going Concern

XML 16 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Dec. 31, 2022

Significant Accounting Policies

Significant Accounting Policies

2. Significant Accounting Policies

(a)

Interim Financial Statements

These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

	(b)	Basis of Presentation
		The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

(c)

Use of Estimates and Judgments

The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to 12 months from the end of the reporting period.

(d)

Recently Adopted Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 17 R9.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities

3 Months Ended

Dec. 31, 2022

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consists of the following:

	December 31, 2022 $		September 30, 2022 $

Accounts payable		684,679		644,970
Accrued interest payable		98,533		79,906

		783,212		724,876

XML 18 R10.htm IDEA: XBRL DOCUMENT

Loans Payable

3 Months Ended

Dec. 31, 2022

Loans Payable

Loans Payable

4.	Loans Payable

(a)

(b)

(c)

As at December 31, 2022, the principal balance owing is $59,077 (September 30, 2022 - $59,077) and the Company has recorded interest payable of $25,447 (September 30, 2022 - $23,664).

XML 19 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes

3 Months Ended

Dec. 31, 2022

Convertible Notes

Convertible Notes

Convertible Notes

(a)

	(b)	On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note was due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity.

		As at December 31, 2022, the carrying value of the convertible note was $78,750 (September 30, 2022 - $78,750) and the fair value of the derivative liability was $104,676 (September 30, 2022 - $260,908).

	(c)	On March 11, 2022, the Company entered into a convertible note with an unrelated party for $30,000, with an advance on January 18, 2022, for the full amount. The note is due on January 18, 2023, and bears interest on the unpaid principal balance at a rate of 10% per annum. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to the closing price on the day of receiving the notice to convert. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $15,011, which reduced the carrying value of the convertible note to $14,989. The carrying value will be accreted over the term of the convertible note up to its face value of $30,000.

		As of December 31, 2022, the carrying value of the convertible notes was $28,742 (September 30, 2022 - $23,489), had an unamortized discount of $1,258 (September 30, 2022 - $6,511), and the fair value of the derivative liability was $5,767 (September 30, 2022 - $10,486). During the three months ended December 31, 2022, the Company recorded accretion expense of $5,253 (2021 - $nil).

	(d)	On November 2, 2022, the Company entered into a secured convertible note with an unrelated party for proceeds of $50,000. The note is due on May 1, 2023 and bears a one-time interest charge of 10% automatically accrued on the issuance date. The one-time interest charge was netted against the convertible note and is being amortized over the term using the effective interest rate method. Stringent pre-payment terms of 25% apply and any amount of principal or interest on the note which is not paid when due shall bear interest at 22% per annum or the highest rate permitted by law.

		The note may be converted at any time after 120 days following the date of issuance into shares of Company’s common stock at a conversion price equal 57.5% of the average of the 3 lowest trading prices during the 15-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging. As the note isn’t convertible until 120 days following issuance, no derivative liability was recognized as of December 31, 2022.

		As of December 31, 2022, the carrying value of the convertible notes was $46,582 (September 30, 2022 - $nil) and had an unamortized discount of $3,418 (September 30, 2022 - $nil). During the three months ended December 31, 2022, the Company recorded accretion expense of $1,582 (2021 - $nil).

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 20 R12.htm IDEA: XBRL DOCUMENT

Derivative Liabilities

3 Months Ended

Dec. 31, 2022

Derivative Liabilities

Derivative Liabilities

Derivative Liabilities

Balance, September 30, 2022	271,394
Change in fair value of embedded conversion option	(160,951	)

Balance, December 31, 2022	110,443

	Expected volatility			Risk-free interest rate			Expected dividend yield			Expected life (in years)

As at September 30, 2022		161	%		3.33	%		0	%		0.26
As at December 31, 2022		217	%		4.38	%		0	%		0.22

XML 21 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Dec. 31, 2022

Related Party Transactions

Related Party Transactions

7.	Related Party Transactions

	(a)	As at December 31, 2022, the Company owed $611,057 (Cdn$828,105) (September 30, 2022 - $588,165 (Cdn$804,285)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the three months ended December 31, 2022, the Company incurred consulting fees of $23,491 (2021 - $23,808) to the President of the Company.

	(b)	As at December 31, 2022, the Company owed $54,236 (Cdn$73,500) (September 30, 2022 - $53,750 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.

	(c)	As at December 31, 2022, the Company owed $40,584 (Cdn$55,000) (September 30, 2022 - $40,221 (Cdn$55,000)) to the father of the President of the Company, which bears interest at 10% per annum, is unsecured and due on June 1, 2026. As of December 31, 2022, the Company recognized accrued interest of $2,386 (Cdn$3,233) (September 30, 2022 – $331 (Cdn$452)).

	(d)	As at December 31, 2022, the Company owed $50,000 (September 30, 2022 - $50,000) to the father of the President of the Company, which bears interest at 10% per annum, is unsecured and due on June 1, 2026. As of December 31, 2022, the Company recognized accrued interest of $2,932 (September 30, 2022 - $387).

	(e)	As at December 31, 2022, the Company owed $25,236 (Cdn$34,200) (September 30, 2022 – $25,010 (Cdn$34,200)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.

	(f)	As at December 31, 2022, the Company owed $534,613 (Cdn$724,508) (September 30, 2022 – $509,610 (Cdn$696,866)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the three months ended December 31, 2022, the Company incurred consulting fees of $23,491 (2021 - $23,808) to the company controlled by the Chief Financial Officer of WFS.

XML 22 R14.htm IDEA: XBRL DOCUMENT

Common Stock

3 Months Ended

Dec. 31, 2022

Common Stock

Common Stock

8.	Common Stock

	Three months ended December 31, 2022

	(a)	On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 for management consulting and strategic business advisory services (Note 12(g)).

	(b)	On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 for product endorsement services (Note 12(h)).

	Three months ended December 31, 2021

	(c)	On October 21, 2021, the Company issued 4,000,000 shares of common stock at $0.025 per common stock for proceeds of $100,000. In connection with the financing, the Company incurred commission fees of $8,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 23 R15.htm IDEA: XBRL DOCUMENT

Preferred Stock

3 Months Ended

Dec. 31, 2022

Common Stock

Preferred Stock

9.	Preferred Stock
	On October 13, 2020, the Company filed a certificate of amendment to its articles of incorporation, whereby it increased the authorized capital to 2,000,000,000 shares of common stock with a par value of $0.001 per share and 1,000,000 preferred shares with a par value of $0.001. On October 14, 2020, the Company designated 10,000 preferred shares as Series A Super Voting Preferred Stock.
	The Series A Super Voting Preferred Stock has the following rights and restrictions:
	Dividends - Initially, there will be no dividends due or payable on the Series A Super Voting Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.
	Liquidation and Redemption Rights - Upon the occurrence of a Liquidation Event, the holders of Series A Super Voting Preferred Stock are entitled to receive net assets on a pro-rata basis. Each holder of Series A Super Voting Preferred Stock is entitled to receive ratably any dividends declared by the Board, if any, out of funds legally available for the payment of dividends.
	Rank - All shares of the Series A Super Voting Preferred Stock shall rank (i) senior to the Corporation’s (A) Common Stock, par value $0.001 per share ( “Common Stock” ), and any other class or series of capital stock of the Corporation hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Section 4, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Super Voting Preferred-Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.
	Voting Rights - If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.
	Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

	·	[twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A, Series A and any newly designated Preferred stock issued and outstanding at the time of voting}] Divided by:

	·	[the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.

XML 24 R16.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants

3 Months Ended

Dec. 31, 2022

Share Purchase Warrants

Share Purchase Warrants

10.

Share Purchase Warrants

The following table summarizes the continuity of the Company’s share purchase warrants:

	Number of warrants			Weighted average exercise price $

Balance, September 30, 2022		58,722,500			0.05

Expired		(5,400,000	)		0.05

Balance, December 31, 2022		53,322,500			0.05

As at December 31, 2022, the following share purchase warrants were outstanding:

Number of warrants		Exercise price		Expiry date

	300,000	$	0.05	January 6, 2023
	2,000,000	$	0.05	January 7, 2023
	2,000,000	$	0.05	January 18, 2023
	300,000	$	0.05	January 25, 2023
	6,000.000	$	0.05	January 27, 2023
	3,400,000	$	0.05	January 28, 2023
	2,800,000	$	0.05	January 30, 2023
	872,500	$	0.05	February 13, 2023
	350,000	$	0.05	February 20, 2023
	2,500,000	$	0.05	April 5, 2023
	600,000	$	0.05	April 7, 2023
	1,000,000	$	0.05	April 12, 2023
	2,250,000	$	0.05	April 15, 2023
	5,100,000	$	0.05	July 1, 2023
	500,000	$	0.05	July 19, 2023
	500,000	$	0.05	July 24, 2023
	2,000,000	$	0.05	September 15, 2023
	650,000	$	0.05	January 19, 2024
	4,800,000	$	0.05	May 19, 2024
	2,400,000	$	0.05	May 20, 2024
	10,000,000	$	0.05	May 26, 2024
	2,000,000	$	0.05	May 27, 2024
	1,000,000	$	0.05	May 30, 2024

	53,322,500

XML 25 R17.htm IDEA: XBRL DOCUMENT

Memorandum of Understanding

3 Months Ended

Dec. 31, 2022

Memorandum of Understanding

Memorandum of Understanding

11.

Memorandum of Understanding

Subsequent to the three months ended December 31, 2022, the Company terminated the MOU. The advance of $88,850 was converted into a note bearing no interest until September 30, 2025.

XML 26 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contigency

3 Months Ended

Dec. 31, 2022

Commitments and Contigency

Commitments and Contigency

12.

Commitments and Contingencies

(a)

(b)

(c)

	(d)	On May 2, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 7,000,000 shares of common stock in exchange for market awareness services. On May 3, 2022, the Company issued 7,000,000 shares of common stock with a fair value of $84,700 pursuant to the agreement. As at December 31, 2022, the Company recognized $nil (September 30, 2022 - $15,191) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $15,191 (2021 - $nil) pursuant to the agreement.

	(e)	On May 20, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,000,000 shares of common stock in exchange for public relations and communications services. If both parties agree to continue the agreement for another 6 months, the Company will issue common stock of the Company with a fair value of $80,000. On August 22, 2022, the Company issued 9,000,000 shares of common stock with a fair value of $81,000 pursuant to the agreement. As at December 31, 2022, the Company recognized $nil (September 30, 2022 - $21,481) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $21,481 (2021 - $nil) pursuant to the agreement.

	(f)	On September 8, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,500,000 shares of common stock in exchange for corporate development, investor, media, public relations, and marketing services. On September 13, 2022, the Company issued 9,500,000 shares of common stock with a fair value of $85,500 pursuant to the agreement. As at December 31, 2022, the Company recognized $31,072 (September 30, 2022 - $75,050) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $43,978 (2021 - $nil) pursuant to the agreement.

	(g)	On September 15, 2022, the Company entered into a consulting agreement with a twelve-month term. Pursuant to the agreement, the Company agreed to issue 2,500,000 shares of common stock in exchange for management consulting and strategic business advisory services. On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 pursuant to the agreement (Note 8(a)). As at December 31, 2022, the Company recognized $19,419 (September 30, 2022 - $nil) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $6,951 (2021 - $nil) pursuant to the agreement.

	(h)	On November 28, 2022, the Company entered into a product endorsement agreement with Tyrell Crosby for an eighteen-month term. Pursuant to the agreement, the Company agreed to issue 10,000,000 shares of common stock in exchange for product endorsement services. On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 pursuant to the agreement (Note 8(b)). As at December 31, 2022, the Company recognized $46,898 (September 30, 2022 - $nil) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $3,102 (2021 - $nil) pursuant to the agreement.

XML 27 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Dec. 31, 2022

Subsequent Events

Subsequent Events

13.	Subsequent Events

	(a)	Subsequent to the three months ended December 31, 2022, the Company terminated the MOU described in Note 11. The advance of $88,850 was converted into a note bearing no interest until September 30, 2025.

	(b)	Subsequent to the three months ended December 31, 2022, a total of 17,672,500 share purchase warrants with an exercise price of $0.05 per share expired unexercised.

XML 28 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2022
Significant Accounting Policies
Interim Financial Statements	These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.
Basis of Presentation	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.
Use of Estimates and Judgments	The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to 12 months from the end of the reporting period.
Recently Adopted Accounting Pronouncements	The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 29 R21.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities (Tables)

3 Months Ended

Dec. 31, 2022

Accounts Payable and Accrued Liabilities

Schedule of Accounts Payable and Accrued Liabilities

	December 31, 2022 $		September 30, 2022 $

Accounts payable		684,679		644,970
Accrued interest payable		98,533		79,906

		783,212		724,876

XML 30 R22.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Tables)

3 Months Ended

Dec. 31, 2022

Derivative Liabilities

Schedule of Derivative Liability

Balance, September 30, 2022	271,394
Change in fair value of embedded conversion option	(160,951	)

Balance, December 31, 2022	110,443

Schedule of analytical assumptions of derivatives

	Expected volatility			Risk-free interest rate			Expected dividend yield			Expected life (in years)

As at September 30, 2022		161	%		3.33	%		0	%		0.26
As at December 31, 2022		217	%		4.38	%		0	%		0.22

XML 31 R23.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants (Tables)

3 Months Ended

Dec. 31, 2022

Share Purchase Warrants

Schedule of Share Purchase Warrants

	Number of warrants			Weighted average exercise price $

Balance, September 30, 2022		58,722,500			0.05

Expired		(5,400,000	)		0.05

Balance, December 31, 2022		53,322,500			0.05

Schedule of Warrants Outstanding

Number of warrants		Exercise price		Expiry date

	300,000	$	0.05	January 6, 2023
	2,000,000	$	0.05	January 7, 2023
	2,000,000	$	0.05	January 18, 2023
	300,000	$	0.05	January 25, 2023
	6,000.000	$	0.05	January 27, 2023
	3,400,000	$	0.05	January 28, 2023
	2,800,000	$	0.05	January 30, 2023
	872,500	$	0.05	February 13, 2023
	350,000	$	0.05	February 20, 2023
	2,500,000	$	0.05	April 5, 2023
	600,000	$	0.05	April 7, 2023
	1,000,000	$	0.05	April 12, 2023
	2,250,000	$	0.05	April 15, 2023
	5,100,000	$	0.05	July 1, 2023
	500,000	$	0.05	July 19, 2023
	500,000	$	0.05	July 24, 2023
	2,000,000	$	0.05	September 15, 2023
	650,000	$	0.05	January 19, 2024
	4,800,000	$	0.05	May 19, 2024
	2,400,000	$	0.05	May 20, 2024
	10,000,000	$	0.05	May 26, 2024
	2,000,000	$	0.05	May 27, 2024
	1,000,000	$	0.05	May 30, 2024

	53,322,500

XML 32 R24.htm IDEA: XBRL DOCUMENT

Nature of Business and Continuance of Operations (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Nature of Business and Continuance of Operations
Working Capital Deficit	$ 1,707,174
Accumulated deficit	(12,614,269)		$ (12,574,895)
Net loss	(39,374)	$ 18,724
Net cash used in operating activities	$ (19,499)	$ (148,530)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 33 R25.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Accounts Payable and Accrued Liabilities
Accounts payable	$ 684,679	$ 644,970
Accrued interest payable	98,533	79,906
Accounts Payable and Accrued Liabilities	$ 783,212	$ 724,876

XML 34 R26.htm IDEA: XBRL DOCUMENT

Loans Payable (Details Narrative)		3 Months Ended	12 Months Ended
Loans Payable (Details Narrative)	Jan. 14, 2020 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($) shares	Dec. 31, 2022 CAD ($)	Aug. 02, 2022 USD ($) shares
Financing costs	$ 3,000
Convertible note debt	$ 78,000
Due date of note			January 14, 2021
Rate of interest			12.00%
Increased Rate of interest			15.00%
Convertible note payable			$ 75,000
Due to related party		$ 90,584	90,221
Convertible note payable		21,885	17,799
Loan payable		128,593	99,077
Promissory Note Nov. 22, 2019 [Member]
Promissory Note with unrelated party		$ 40,000
Interest rate		10.00%
Accured Interest Payable		$ 12,415	11,408
Loan Payable April 22, 2020 [Member]
Loan payable		29,516	29,252
CANADA \| Loan Payable April 22, 2020 [Member]
Loan Receivable				$ 40,000
Preferred Stocks [Member]
Loans payable		40,000	40,000
Due to related party		59,077	59,077
Interest payable		$ 25,447	23,664
Shares of common stock received \| shares					660,300
Convertible note payable					$ 59,077
Derivative liability					$ 163,760
Default penalty			$ 53,007
Common stock fair value \| shares			660,300
Recovery of default penalties			$ 4,606
Loan forgiveness description		If the Company repays the loan prior to December 31, 2023, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000

XML 35 R27.htm IDEA: XBRL DOCUMENT

Convertible Notes (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
Convertible Notes (Details Narrative) - USD ($)	Apr. 04, 2018	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Mar. 11, 2022	Oct. 13, 2020	Jan. 14, 2020
Unamortized discount		$ 5,183			$ 9,269
Carrying value of convertible notes		21,885		$ 17,799
Accretion Expense		$ 4,086			$ 1,799
Convertible notes									$ 78,000
Due date of note				January 14, 2021
Rate of interest				12.00%
Common Stock, Par Value		$ 0.001		$ 0.001				$ 0.001
Convertible Note [Member]
Beneficial conversion feature	$ 32,485
Due date of note	April 4, 2023
Rate of interest	12.00%
Face value of convertible notes	$ 32,485
Amount Owed to Related Party	$ 32,485
Common Stock, Par Value	$ 0.0001
January 22, 2020 [Member] \| Unrelated party [Member]
Carrying value of convertible notes		$ 78,750		$ 78,750
Accretion Expense						$ 78,250
Description of conversion of convertible notes		The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date
Fair value of the derivative liability		$ 104,676		260,908
Beneficial conversion feature		75,179
Convertible notes		78,750
Directly paid to third party for financing		9,750
Proceeds from convertible debt		$ 69,000
Due date of note		January 22, 2021
Rate of interest		10.00%
Rate of interest on unpaid balance after default of note		24.00%
Maximum intrinsic value of the embedded beneficial conversion feature		$ 68,500
Loss on change in fair value of derivative		6,679
Face value of convertible notes		78,750
Reduced carrying value of convertible note		500
March 11 2022 [Member] \| Convertible Note [Member]
Carrying value of convertible notes		14,989
Accretion Expense		5,253	$ 0
Fair value of the derivative liability		5,767		10,486
Beneficial conversion feature		15,011
Convertible notes		$ 28,742		23,489			$ 30,000
Rate of interest		10.00%
Face value of convertible notes		$ 30,000
Remaining debt discount		1,258		6,511
November 2, 2022 [Member] \| Unrelated party [Member]
Unamortized discount		3,418		0
Carrying value of convertible notes		46,582		$ 0
Accretion Expense		$ 1,582	$ 0
Description of conversion of convertible notes		The note may be converted at any time after 120 days following the date of issuance into shares of Company’s common stock at a conversion price equal 57.5% of the average of the 3 lowest trading prices during the 15-trading day period prior to the conversion date
Fair value of the derivative liability		$ 0
Proceeds from convertible debt		$ 50,000
Due date of note		May 1, 2023
Rate of interest		10.00%
Rate of interest on unpaid balance after default of note		22.00%
Rate of stringent pre-payment		25.00%

XML 36 R28.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Details)	3 Months Ended
Derivative Liabilities (Details)	Dec. 31, 2022 USD ($)
Derivative Liabilities
Derivative Liability, beginning	$ 271,394
Change in fair value of embedded conversion option	(160,951)
Derivative Liability, ending	$ 110,443

XML 37 R29.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Details 1) - Derivative Liability [Member]	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Expected volatility	217.00%	161.00%
Risk-free interest rate	4.38%	3.33%
Expected dividend yield	0.00%	0.00%
Expected life	2 months 19 days	3 months 3 days

XML 38 R30.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative)	3 Months Ended
Related Party Transactions (Details Narrative)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 CAD ($)
Due to Related Parties	$ 665,293		$ 641,915
President [Member]
Due to Related Parties	611,057		588,165
Consulting Fees	23,491		23,808
President [Member] \| CANADA
Due to Related Parties		$ 828,105		$ 804,285
Father of President [Member]
Due to Related Parties	54,236		53,750
Father of President [Member] \| CANADA
Due to Related Parties		73,500		73,500
Father of President One [Member]
Due to Related Parties	$ 40,584		40,221
Interest rate	10.00%
Accrued interest	$ 2,386		331
Father of President One [Member] \| CANADA
Due to Related Parties		55,000		55,000
Accrued interest	3,233		452
Company Controller By Chief Financial Officer [Member]
Due to Related Parties	534,613		509,610
Consulting Fees	23,491		23,808
Company Controller By Chief Financial Officer [Member] \| CANADA
Due to Related Parties		$ 724,508		$ 696,866
Father of President Two [Member]
Due to Related Parties	$ 50,000		50,000
Interest rate	10.00%
Accrued interest	$ 2,932		387
Father of President Three [Member]
Due to Related Parties	25,236		25,010
Father of President Three [Member] \| CANADA
Due to Related Parties	$ 34,200		$ 34,200

XML 39 R31.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)	3 Months Ended
Common Stock (Details Narrative) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Proceeds from issuance of common stock	$ 0	$ 92,000
October 21, 2021 [Member]
Proceeds from issuance of common stock	$ 100,000
Common stock shares issued for services, shares	4,000,000
Common stock shares issued for services, amount	$ 8,000
Common stock shares issued price per share	$ 0.025
October 3, 2022 [Member]
Common stock shares issued for services, shares	2,500,000
Common stock shares issued for services, amount	$ 27,500
December 14, 2022
Common stock shares issued for services, shares	10,000,000
Common stock shares issued for services, amount	$ 50,000

XML 40 R32.htm IDEA: XBRL DOCUMENT

Preferred Stock (Details Narrative) - USD ($)	Dec. 31, 2022	Sep. 30, 2022	Oct. 14, 2020	Oct. 13, 2020
Preferred stock authorized	1,000,000	1,000,000		1,000,000
Preferred stock par value	$ 0.001	$ 0.001		$ 0.001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000		2,000,000,000
Common Stock, Par Value	$ 0.001	$ 0.001		$ 0.001
Issuance Of preferred stock, shares	10,000	10,000
Issuance Of preferred stock, value	$ 10	$ 10
Series A Super Voting Preferred Stock [Member]
Issuance Of preferred stock, shares			10,000
Issuance Of preferred stock, value			$ 10
Preferred Stock designated			10,000

XML 41 R33.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants (Details) - Warrant [Member]	3 Months Ended
Share Purchase Warrants (Details) - Warrant [Member]	Dec. 31, 2022 $ / shares shares
Beginning Balance \| shares	58,722,500
Expired \| shares	(5,400,000)
Ending Balance \| shares	53,322,500
Weighted average exercise price, beginning \| $ / shares	$ 0.05
Weighted average exercise price,Expired \| $ / shares	0.05
Weighted average exercise price, ending \| $ / shares	$ 0.05

XML 42 R34.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants (Details 1)	3 Months Ended
Share Purchase Warrants (Details 1)	Dec. 31, 2022 $ / shares shares
Number of warrants	53,322,500
Warrants Sixteen [Member]
Number of warrants	500,000
Exercise price \| $ / shares	$ 0.05
Expiry date	July 24, 2023
Warrants Seventeen [Member]
Number of warrants	2,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	September 15, 2023
Warrants Nineteen [Member]
Number of warrants	4,800,000
Exercise price \| $ / shares	$ 0.05
Expiry date	May 19, 2024
Warrants Twenty One [Member]
Number of warrants	10,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	May 26, 2024
Warrants Twenty [Member]
Number of warrants	2,400,000
Exercise price \| $ / shares	$ 0.05
Expiry date	May 20, 2024
Warrants Eighteen [Member]
Number of warrants	650,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 19, 2024
Warrants Twenty Two [Member]
Number of warrants	2,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	May 27, 2024
Warrants Twenty Three [Member]
Number of warrants	1,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	May 30, 2024
Warrant One [Member]
Number of warrants	300,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 6, 2023
Warrant Two [Member]
Number of warrants	2,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 7, 2023
Warrant Three [Member]
Number of warrants	2,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 18, 2023
Warrant Four [Member]
Number of warrants	300,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 25, 2023
Warrant Five [Member]
Number of warrants	6,000.000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 27, 2023
Warrant Six [Member]
Number of warrants	3,400,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 28, 2023
Warrant Seven [Member]
Number of warrants	2,800,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 30, 2023
Warrant Eight [Member]
Number of warrants	872,500
Exercise price \| $ / shares	$ 0.05
Expiry date	February 13, 2023
Warrant Nine [Member]
Number of warrants	350,000
Exercise price \| $ / shares	$ 0.05
Expiry date	February 20, 2023
Warrant Ten [Member]
Number of warrants	2,500,000
Exercise price \| $ / shares	$ 0.05
Expiry date	April 5, 2023
Warrant Eleven [Member]
Number of warrants	600,000
Exercise price \| $ / shares	$ 0.05
Expiry date	April 7, 2023
Warrants Twelve [Member]
Number of warrants	1,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	April 12, 2023
Warrants Thirteen [Member]
Number of warrants	2,250,000
Exercise price \| $ / shares	$ 0.05
Expiry date	April 15, 2023
Warrants Fourteen [Member]
Number of warrants	5,100,000
Exercise price \| $ / shares	$ 0.05
Expiry date	July 1, 2023
Warrants Fifteen [Member]
Number of warrants	500,000
Exercise price \| $ / shares	$ 0.05
Expiry date	July 19, 2023

XML 43 R35.htm IDEA: XBRL DOCUMENT

Memorandum of Understanding (Details Narrative) - M O U [Member] - USD ($)	1 Months Ended
	Jul. 25, 2021	Dec. 31, 2022	Sep. 30, 2022
Amount advanced		$ 88,850	$ 88,850
Acquisition price	$ 2,400,000

XML 44 R36.htm IDEA: XBRL DOCUMENT

Commitments and Contigency (Details Narrative)							1 Months Ended				3 Months Ended
Commitments and Contigency (Details Narrative)	Sep. 13, 2022	Sep. 08, 2022	May 02, 2022	May 14, 2021	Jan. 25, 2019 USD ($) shares	Jan. 25, 2019 CAD ($) shares	Sep. 15, 2022	May 20, 2022	Sep. 23, 2021	Nov. 22, 2019 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 14, 2022 shares	Oct. 03, 2022 shares	Sep. 30, 2022 USD ($) shares	Mar. 10, 2021 USD ($)
Lieu of Complaint notice amount																$ 40,504
Lieu of Complaint notice Interest rate																10.00%
Lieu of Complaint notice Description									the noteholder filed a new Notice of Motion for Summary Judgement in Lieu of Complaint with the State of New York Supreme Court, County of New York for $44,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. The plaintiff filed for an oral argument which was heard by the State of New York Supreme Court on September 15, 2022 and is pending a final decision. The Company believes that the claim has no merit and intends to defend its position vigorously
Consulting Fee											$ 139,905	$ 139,528
Number of common share issued \| shares											454,760,969				442,260,969
Advances from Alliance Growers Corp											$ 55,342				$ 54,847
Novation Solutions Inc [Member]
Service agreement fee payable description				The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 30 days prior to launching the portal, and a post launch monthly fee of $1,000
Alliance Growers Corp. [Member]
Advances from Alliance Growers Corp											55,342				54,847
Option consideration					$ 1,018,182
Option agreement grants					The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000.	The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000.
Common Stock Issued upon exercise of the option (in Shares) \| shares					8	8
Alliance Growers Corp. [Member] \| CANADA
Advances from Alliance Growers Corp											75,000				75,000
Common Stock Issued upon exercise of the option, value						$ 1,350,008
Consulting Agreement May 2, 2022 [Member]
Consulting Fee											15,191	0
Agreement descriptions			the Company issued 7,000,000 shares of common stock with a fair value of $84,700 pursuant to the agreement
Prepaid expenses and deposits											15,191
Fair value											$ 84,700
Common stock shares issued consulting services \| shares											7,000,000
Consulting Agreement May 20, 2022 [Member]
Consulting Fee											$ 21,481	0
Agreement descriptions								the Company agreed to issue 9,000,000 shares of common stock in exchange for public relations and communications services
Prepaid expenses and deposits											0				21,481
Fair value											$ 80,000
Common stock shares issued consulting services \| shares											9,000,000
Common stock shares issued Fair value											$ 81,000
Consulting Agreement Sep 8, 2022 [Member]
Agreement descriptions	the Company issued 9,500,000 shares of common stock with a fair value of $85,500 pursuant to the agreement	the Company agreed to issue 9,500,000 shares of common stock in exchange for corporate development, investor, media, public relations, and marketing services
Prepaid expenses and deposits											31,072				75,050
Consulting Fee											43,978	0
Consulting Agreement Sep 15, 2022 [Member]
Agreement descriptions							the Company agreed to issue 2,500,000 shares of common stock in exchange for management consulting and strategic business advisory services. On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 pursuant to the agreement (Note 8(a))
Prepaid expenses and deposits											19,419				0
Consulting Fee											6,951	0
Number of common share issued \| shares														2,500,000
Equity Purchase Agreement [Member]
Promissory Note with unrelated party										$ 40,000
Maximun shares purchase under agreement \| shares										10,000,000
Purchase price description										The purchase price would be 85% of the market price
Additional commitment fee description										the Company is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing
Consulting Agreement November 28, 2022 [Member]
Agreement descriptions							the Company agreed to issue 10,000,000 shares of common stock in exchange for product endorsement services. On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 pursuant to the agreement (Note 8(b))
Prepaid expenses and deposits											46,898				$ 0
Consulting Fee											$ 3,102	$ 0
Number of common share issued \| shares													10,000,000

XML 45 R37.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative)	3 Months Ended
Subsequent Events (Details Narrative)	Dec. 31, 2022 USD ($) $ / shares shares
Subsequent Events
Convertible promissory note \| $	$ 88,850
Class of Warrant or Right, Expired \| shares	17,672,500
Exercise price \| $ / shares	$ 0.05

XML 46 phbi_10q_htm.xml IDEA: XBRL DOCUMENT 0001435181 2022-10-01 2022-12-31 0001435181 phbi:CAMember phbi:AllianceGrowersCorpMember 2019-01-24 2019-01-25 0001435181 phbi:AllianceGrowersCorpMember 2019-01-24 2019-01-25 0001435181 phbi:CAMember phbi:AllianceGrowersCorpMember 2022-12-31 0001435181 phbi:CAMember phbi:AllianceGrowersCorpMember 2022-09-30 0001435181 phbi:AllianceGrowersCorpMember 2022-12-31 0001435181 phbi:AllianceGrowersCorpMember 2022-09-30 0001435181 phbi:NovationSolutionsIncMember 2021-05-01 2021-05-14 0001435181 phbi:EquityPurchaseAgreementMember 2019-11-01 2019-11-22 0001435181 phbi:EquityPurchaseAgreementMember 2019-11-22 0001435181 phbi:ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember 2022-12-14 0001435181 phbi:ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember 2022-10-03 0001435181 phbi:ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:ConsultingAgreementSeptemberEightTwentyTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember 2021-10-01 2021-12-31 0001435181 phbi:ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember 2021-10-01 2021-12-31 0001435181 phbi:ConsultingAgreementSeptemberEightTwentyTwentyTwoMember 2021-10-01 2021-12-31 0001435181 phbi:ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:ConsultingAgreementMayTwoTwoThousandTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember 2021-10-01 2021-12-31 0001435181 phbi:ConsultingAgreementMayTwoTwoThousandTwentyTwoMember 2021-10-01 2021-12-31 0001435181 phbi:ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember 2022-09-30 0001435181 phbi:ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember 2022-09-30 0001435181 phbi:ConsultingAgreementSeptemberEightTwentyTwentyTwoMember 2022-09-30 0001435181 phbi:ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember 2022-09-30 0001435181 phbi:ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember 2022-12-31 0001435181 phbi:ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember 2022-12-31 0001435181 phbi:ConsultingAgreementSeptemberEightTwentyTwentyTwoMember 2022-12-31 0001435181 phbi:ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember 2022-12-31 0001435181 phbi:ConsultingAgreementMayTwoTwoThousandTwentyTwoMember 2022-12-31 0001435181 phbi:ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember 2022-09-01 2022-09-15 0001435181 phbi:ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember 2022-09-01 2022-09-15 0001435181 phbi:ConsultingAgreementSeptemberEightTwentyTwentyTwoMember 2022-09-02 2022-09-13 0001435181 phbi:ConsultingAgreementSeptemberEightTwentyTwentyTwoMember 2022-09-03 2022-09-08 0001435181 phbi:ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember 2022-05-01 2022-05-20 0001435181 phbi:ConsultingAgreementMayTwoTwoThousandTwentyTwoMember 2022-05-01 2022-05-02 0001435181 2021-09-01 2021-09-23 0001435181 2021-03-10 0001435181 phbi:MOUMember 2021-07-01 2021-07-25 0001435181 phbi:MOUMember 2022-09-30 0001435181 phbi:MOUMember 2022-12-31 0001435181 phbi:WarrantsFifteenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsFourteenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTwentyThreeMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTwentyOneMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTwentyMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsNineteenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsEighteenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsSixteenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsSeventeenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsNineMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsThirteenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTwelveMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsElevenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsEightMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsSevenMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsSixMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsFiveMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsFourMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsThreeMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsTwoMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsOneMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsMember 2022-12-31 0001435181 phbi:WarrantsMember 2022-10-01 2022-12-31 0001435181 phbi:WarrantsMember 2022-09-30 0001435181 2020-10-13 0001435181 phbi:SeriesASuperVotingPreferredStockMember 2020-10-14 0001435181 phbi:DecemberFourteenTwoThousandTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:OctoberThreeTwoThousandTwentyTwoMember 2022-10-01 2022-12-31 0001435181 phbi:OctoberTwentyOneTwoThousandTwentyOneMember 2022-12-31 0001435181 phbi:OctoberTwentyOneTwoThousandTwentyOneMember 2022-10-01 2022-12-31 0001435181 phbi:CAMember phbi:CompanyControllerByChiefFinancialOfficerMember 2022-12-31 0001435181 phbi:CompanyControllerByChiefFinancialOfficerMember 2022-12-31 0001435181 phbi:CAMember phbi:CompanyControllerByChiefFinancialOfficerMember 2022-09-30 0001435181 phbi:CompanyControllerByChiefFinancialOfficerMember 2022-09-30 0001435181 phbi:CAMember phbi:FatherOfPresidentThreeMember 2022-12-31 0001435181 phbi:FatherOfPresidentThreeMember 2022-12-31 0001435181 phbi:CAMember phbi:FatherOfPresidentThreeMember 2022-09-30 0001435181 phbi:FatherOfPresidentThreeMember 2022-09-30 0001435181 phbi:FatherOfPresidentTwoMember 2022-09-30 0001435181 phbi:FatherOfPresidentTwoMember 2022-12-31 0001435181 phbi:FatherOfPresidentTwoMember 2022-10-01 2022-12-31 0001435181 phbi:CAMember phbi:FatherOfPresidentOneMember 2022-09-30 0001435181 phbi:CAMember phbi:FatherOfPresidentOneMember 2022-12-31 0001435181 phbi:FatherOfPresidentOneMember 2022-12-31 0001435181 phbi:FatherOfPresidentOneMember 2022-10-01 2022-12-31 0001435181 phbi:FatherOfPresidentOneMember 2022-09-30 0001435181 phbi:CAMember phbi:FatherOfPresidentMember 2022-09-30 0001435181 phbi:FatherOfPresidentMember 2022-12-31 0001435181 phbi:CAMember phbi:FatherOfPresidentMember 2022-12-31 0001435181 phbi:FatherOfPresidentMember 2022-09-30 0001435181 phbi:CAMember srt:PresidentMember 2022-12-31 0001435181 srt:PresidentMember 2022-12-31 0001435181 phbi:CAMember srt:PresidentMember 2022-09-30 0001435181 srt:PresidentMember 2022-09-30 0001435181 phbi:DerivativeLiabilityMember 2021-10-01 2022-09-30 0001435181 phbi:DerivativeLiabilityMember 2022-10-01 2022-12-31 0001435181 phbi:ConvertibleNoteMember 2018-04-04 0001435181 phbi:MarchElevenTwentyTwentyTwoMember phbi:ConvertibleNoteMember 2022-03-11 0001435181 phbi:ConvertibleNoteMember 2018-04-03 2018-04-04 0001435181 phbi:MarchElevenTwentyTwentyTwoMember phbi:ConvertibleNoteMember 2022-09-30 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2022-10-01 2022-12-31 0001435181 phbi:NovemberSecondTwoThousandTwentyTwoMember phbi:UnrelatedPartyMember 2021-10-01 2021-12-31 0001435181 phbi:MarchElevenTwentyTwentyTwoMember phbi:ConvertibleNoteMember 2021-10-01 2021-12-31 0001435181 phbi:MarchElevenTwentyTwentyTwoMember phbi:ConvertibleNoteMember 2022-10-01 2022-12-31 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2019-10-01 2020-09-30 0001435181 2020-10-01 2021-09-30 0001435181 phbi:NovemberSecondTwoThousandTwentyTwoMember phbi:UnrelatedPartyMember 2022-10-01 2022-12-31 0001435181 phbi:NovemberSecondTwoThousandTwentyTwoMember phbi:UnrelatedPartyMember 2021-10-01 2022-09-30 0001435181 phbi:NovemberSecondTwoThousandTwentyTwoMember phbi:UnrelatedPartyMember 2022-09-30 0001435181 phbi:NovemberSecondTwoThousandTwentyTwoMember phbi:UnrelatedPartyMember 2022-12-31 0001435181 phbi:MarchElevenTwentyTwentyTwoMember phbi:ConvertibleNoteMember 2022-12-31 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2022-09-30 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2022-12-31 0001435181 phbi:LoansPayable1Member 2022-09-30 0001435181 phbi:LoansPayable1Member 2022-10-01 2022-12-31 0001435181 phbi:LoansPayable1Member 2022-12-31 0001435181 phbi:CAMember phbi:LoansPayable2Member 2022-12-31 0001435181 phbi:PreferredStocksOneMember 2022-10-01 2022-12-31 0001435181 phbi:PreferredStocksOneMember 2021-10-01 2022-09-30 0001435181 phbi:LoanPayableAprilTwentyTwoTwentyThousandyTwentyMember 2022-12-31 0001435181 2021-10-01 2022-09-30 0001435181 2020-01-14 0001435181 2020-01-01 2020-01-14 0001435181 phbi:LoanPayableAprilTwentyTwoTwentyThousandyTwentyMember 2022-09-30 0001435181 phbi:PreferredStocksOneMember 2022-08-02 0001435181 phbi:PreferredStocksOneMember 2022-09-30 0001435181 phbi:PreferredStocksOneMember 2022-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2022-12-31 0001435181 us-gaap:RetainedEarningsMember 2022-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001435181 phbi:CommonStockIssuableMember 2022-12-31 0001435181 us-gaap:CommonStockMember 2022-12-31 0001435181 us-gaap:PreferredStockMember 2022-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2022-10-01 2022-12-31 0001435181 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001435181 phbi:CommonStockIssuableMember 2022-10-01 2022-12-31 0001435181 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001435181 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2022-09-30 0001435181 us-gaap:RetainedEarningsMember 2022-09-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001435181 phbi:CommonStockIssuableMember 2022-09-30 0001435181 us-gaap:CommonStockMember 2022-09-30 0001435181 us-gaap:PreferredStockMember 2022-09-30 0001435181 2021-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2021-12-31 0001435181 us-gaap:RetainedEarningsMember 2021-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001435181 phbi:CommonStockIssuableMember 2021-12-31 0001435181 us-gaap:CommonStockMember 2021-12-31 0001435181 us-gaap:PreferredStockMember 2021-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2021-10-01 2021-12-31 0001435181 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001435181 phbi:CommonStockIssuableMember 2021-10-01 2021-12-31 0001435181 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001435181 us-gaap:PreferredStockMember 2021-10-01 2021-12-31 0001435181 2021-09-30 0001435181 us-gaap:NoncontrollingInterestMember 2021-09-30 0001435181 us-gaap:RetainedEarningsMember 2021-09-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001435181 phbi:CommonStockIssuableMember 2021-09-30 0001435181 us-gaap:CommonStockMember 2021-09-30 0001435181 us-gaap:PreferredStockMember 2021-09-30 0001435181 2021-10-01 2021-12-31 0001435181 2022-09-30 0001435181 2022-12-31 0001435181 2023-02-14 iso4217:USD shares iso4217:USD shares pure iso4217:CAD 0001435181 false --09-30 Q1 2023

0.001

1000000

10000

0.001

2000000000

442260969

454760969

0 0 0 0 0 0 0 0 10000000 10-Q true 2022-12-31 false 000-56090 PHARMAGREEN BIOTECH INC. NV 92-1737808 2987 Blackbear Court Coquitlam BC V3E 3A2 702 803-9404 Yes No Non-accelerated Filer true false false 454760969

24964

8016

465

383

186239

200572

211668

208971

783212

724876

55342 54847

128593

99077

9859

15780

175959

120038

110443

271394

665293

641915

1918842

1912147

29252

90584

90221

2009426

2031620

1000000

0.001

10000

2000000000

0.001

454760969

442260969

454761

442261

0 1130

10326777

10261777

81648

93753

-12614269

-12574895

-1751073

-1775964

-46685

-1797758

-1822649

211668

208971

139905 139528

2847

-576

17756

27213

24472

31459

1807

4884

181093

203660

-181093

-203660

-10921

-1799

8311

10091

160951

234274

141719

222384

-39374

18724

-39374

18724

-12105

-2463

-51479

16261

-0.00 0.00 446527273 384214747

10000

381171269

381171

9680572

-8378

-11699417

-46658

-1692700

4000000

4000

88000

92000

-2463

18724

10000

385171269

385171

9768572

-10841

-11680693

-46658

-1584439

10000

442260969

442261

1130

10261777

93753

-12574895

-46685

-1822649

12500000

12500 -1130 65000 0 0 0 76370

-12105

-39374

10000

454760969

454761

10326777

81648

-12614269

-46685

-1797758

39374

-18724

10921 1799

160951

234274

76370

-228

-14333

-274

53336

40017

25948

24702

-19499

-148530

50000

92000

50000

2570

6041

47430

135959

-10983

-2255

16948

-14826

8016

25300

24964

10474

1707174

-12614269

-39374

-19499

2. Significant Accounting Policies <table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(a)</td><td style="vertical-align:top;">Interim Financial Statements</td></tr><tr style="height:15px"><td> </td><td> </td><td> These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"/><td style="width:4%;vertical-align:top;">(b)</td><td style="vertical-align:top;">Basis of Presentation</td></tr><tr style="height:15px"><td/><td/><td>The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(c)</td><td style="vertical-align:top;">Use of Estimates and Judgments</td></tr><tr style="height:15px"><td> </td><td> </td><td>The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to 12 months from the end of the reporting period.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(d)</td><td style="vertical-align:top;">Recently Adopted Accounting Pronouncements</td></tr><tr style="height:15px"><td> </td><td> </td><td> The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</td></tr></tbody></table>

These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 BC Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the equity component of convertible notes, fair value of derivative liabilities, fair value of stock-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to 12 months from the end of the reporting period.

The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31,2022$</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30,2022$</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">684,679</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">644,970</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued interest payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">98,533</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">79,906</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">783,212</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">724,876</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

684679

644970

98533

79906

783212

724876

40000

0.10

12415

11408

40000

29516

40000

29252

40000

If the Company repays the loan prior to December 31, 2023, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000

78000

3000

75000 January 14, 2021 0.12 0.15 660300

59077

163760

53007

660300

4606

59077

25447

23664

<table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td>5.</td><td colspan="2" style="vertical-align:top;">Convertible Notes </td></tr><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;"> (a)</td><td style="vertical-align:top;"> On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the commitment date, and the convertible notes contained a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $32,485 as additional paid-in capital and reduced the carrying value of the convertible note to $nil. The carrying value will be accreted over the term of the convertible notes up to their face value of $32,485.</td></tr><tr style="height:15px"><td> </td><td> </td><td style="vertical-align:top;"> As of December 31, 2022, the carrying value of the convertible notes was $21,885 (September 30, 2022 - $17,799) and had an unamortized discount of $5,183 (September 30, 2022 - $9,269). During the three months ended December 31, 2022, the Company recorded accretion expense of $4,086 (2021 - $1,799).</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"/><td style="width:4%;vertical-align:top;">(b)</td><td style="vertical-align:top;">On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note was due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td/><td style="vertical-align:top;">The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td/><td style="vertical-align:top;">As at December 31, 2022, the carrying value of the convertible note was $78,750 (September 30, 2022 - $78,750) and the fair value of the derivative liability was $104,676 (September 30, 2022 - $260,908).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(c)</td><td style="vertical-align:top;">On March 11, 2022, the Company entered into a convertible note with an unrelated party for $30,000, with an advance on January 18, 2022, for the full amount. The note is due on January 18, 2023, and bears interest on the unpaid principal balance at a rate of 10% per annum. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to the closing price on the day of receiving the notice to convert. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $15,011, which reduced the carrying value of the convertible note to $14,989. The carrying value will be accreted over the term of the convertible note up to its face value of $30,000.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td/><td style="vertical-align:top;">As of December 31, 2022, the carrying value of the convertible notes was $28,742 (September 30, 2022 - $23,489), had an unamortized discount of $1,258 (September 30, 2022 - $6,511), and the fair value of the derivative liability was $5,767 (September 30, 2022 - $10,486). During the three months ended December 31, 2022, the Company recorded accretion expense of $5,253 (2021 - $nil).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(d)</td><td style="vertical-align:top;">On November 2, 2022, the Company entered into a secured convertible note with an unrelated party for proceeds of $50,000. The note is due on May 1, 2023 and bears a one-time interest charge of 10% automatically accrued on the issuance date. The one-time interest charge was netted against the convertible note and is being amortized over the term using the effective interest rate method. Stringent pre-payment terms of 25% apply and any amount of principal or interest on the note which is not paid when due shall bear interest at 22% per annum or the highest rate permitted by law. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td/><td style="vertical-align:top;">The note may be converted at any time after 120 days following the date of issuance into shares of Company’s common stock at a conversion price equal 57.5% of the average of the 3 lowest trading prices during the 15-trading day period prior to the conversion date. Due to this provision, the Company considered whether the embedded conversion option qualifies for derivative accounting under ASC 815-15 Derivatives and Hedging. As the note isn’t convertible until 120 days following issuance, no derivative liability was recognized as of December 31, 2022.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td/><td style="vertical-align:top;">As of December 31, 2022, the carrying value of the convertible notes was $46,582 (September 30, 2022 - $nil) and had an unamortized discount of $3,418 (September 30, 2022 - $nil). During the three months ended December 31, 2022, the Company recorded accretion expense of $1,582 (2021 - $nil). </td></tr></tbody></table>

32485

April 4, 2023

0.0001

0.12

32485

21885

17799

5183

9269

4086

1799

78750

9750

69000

January 22, 2021 0.10 0.24 The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date

75179

68500

6679

500

78750

78250

78750

104676

260908

30000

0.10

15011

14989

30000

28742

23489

1258

6511

5767

10486

5253

50000

May 1, 2023 0.10 0.25 0.22 The note may be converted at any time after 120 days following the date of issuance into shares of Company’s common stock at a conversion price equal 57.5% of the average of the 3 lowest trading prices during the 15-trading day period prior to the conversion date

46582

3418

1582

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">6. </td><td style="vertical-align:top;">Derivative Liabilities</td></tr><tr style="height:15px"><td> </td><td> The embedded conversion option of the Company’s convertible notes described in Note 5 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">271,394</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value of embedded conversion option</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(160,951</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">110,443</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td>The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using the binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the assumptions used in the calculations: </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expectedvolatility</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Risk-free interest rate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expected dividend yield</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expected life (in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As at September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.26</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">As at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.38</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.22</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">271,394</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value of embedded conversion option</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(160,951</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">110,443</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

271394

-160951

110443

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expectedvolatility</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Risk-free interest rate</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expected dividend yield</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expected life (in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As at September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">161</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.26</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">As at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.38</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.22</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1.61

0.0333

P0Y3M3D

2.17

0.0438

P0Y2M19D

<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">7.</td><td colspan="2" style="vertical-align:top;">Related Party Transactions</td></tr><tr style="height:15px"><td> </td><td colspan="2"> </td></tr><tr style="height:15px"><td style="width:4%;"/><td style="width:4%;vertical-align:top;">(a)</td><td style="vertical-align:top;">As at December 31, 2022, the Company owed $611,057 (Cdn$828,105) (September 30, 2022 - $588,165 (Cdn$804,285)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the three months ended December 31, 2022, the Company incurred consulting fees of $23,491 (2021 - $23,808) to the President of the Company. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(b)</td><td style="vertical-align:top;">As at December 31, 2022, the Company owed $54,236 (Cdn$73,500) (September 30, 2022 - $53,750 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(c)</td><td style="vertical-align:top;">As at December 31, 2022, the Company owed $40,584 (Cdn$55,000) (September 30, 2022 - $40,221 (Cdn$55,000)) to the father of the President of the Company, which bears interest at 10% per annum, is unsecured and due on June 1, 2026. As of December 31, 2022, the Company recognized accrued interest of $2,386 (Cdn$3,233) (September 30, 2022 – $331 (Cdn$452)).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(d)</td><td style="vertical-align:top;">As at December 31, 2022, the Company owed $50,000 (September 30, 2022 - $50,000) to the father of the President of the Company, which bears interest at 10% per annum, is unsecured and due on June 1, 2026. As of December 31, 2022, the Company recognized accrued interest of $2,932 (September 30, 2022 - $387).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(e)</td><td style="vertical-align:top;">As at December 31, 2022, the Company owed $25,236 (Cdn$34,200) (September 30, 2022 – $25,010 (Cdn$34,200)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td/><td style="vertical-align:top;">(f)</td><td style="vertical-align:top;">As at December 31, 2022, the Company owed $534,613 (Cdn$724,508) (September 30, 2022 – $509,610 (Cdn$696,866)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the three months ended December 31, 2022, the Company incurred consulting fees of $23,491 (2021 - $23,808) to the company controlled by the Chief Financial Officer of WFS.</td></tr></tbody></table>

611057

828105

588165

804285

23491 23808

54236

73500

53750

73500

40584

55000

40221

55000

0.10

2386

3233

331

452

50000

0.10

2932

387

25236

34200

25010

34200

534613

724508

509610

696866

23491 23808

2500000

27500

10000000

50000

4000000

0.025

100000

8000

<table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">9.</td><td style="vertical-align:top;">Preferred Stock </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On October 13, 2020, the Company filed a certificate of amendment to its articles of incorporation, whereby it increased the authorized capital to 2,000,000,000 shares of common stock with a par value of $0.001 per share and 1,000,000 preferred shares with a par value of $0.001. On October 14, 2020, the Company designated 10,000 preferred shares as Series A Super Voting Preferred Stock.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> The Series A Super Voting Preferred Stock has the following rights and restrictions:</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> Dividends - Initially, there will be no dividends due or payable on the Series A Super Voting Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> Liquidation and Redemption Rights - Upon the occurrence of a Liquidation Event, the holders of Series A Super Voting Preferred Stock are entitled to receive net assets on a pro-rata basis. Each holder of Series A Super Voting Preferred Stock is entitled to receive ratably any dividends declared by the Board, if any, out of funds legally available for the payment of dividends.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> Rank - All shares of the Series A Super Voting Preferred Stock shall rank (i) senior to the Corporation’s (A) Common Stock, par value $0.001 per share ( “Common Stock” ), and any other class or series of capital stock of the Corporation hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Section 4, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Super Voting Preferred-Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> Voting Rights - If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">[twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A, Series A and any newly designated Preferred stock issued and outstanding at the time of voting}] Divided by:</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">[the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td colspan="3">With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.</td></tr></tbody></table>Protective Provisions So long as any shares of Series A Super Voting Preferred Stock are outstanding, the Corporation shall not, without first obtaining the unanimous written consent of the holders of Series A Super Voting Preferred Stock, alter or change the rights, preferences or privileges of the Series A Super Voting Preferred so as to affect adversely the holders of Series A Super Voting Preferred Stock. On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a Director of the Company for proceeds of $10. In connection with the issuance of the Series A Super Voting Preferred Stock, the Company evaluated whether the preferred stock should be classified as a liability based on the guidance under ASC 480, Distinguishing Liabilities from Equity. The Series A Super Voting Preferred Stock are not considered mandatorily redeemable, are not settleable in a variable number of shares, and do not contain any features embedded that required a separate assessment. As a result, the Company determined the Series A Super Voting Preferred Stock were not a liability and classified the preferred stock within equity in the amount of the aggregate par value of the issued shares of preferred stock, with any excess attributed to additional paid-in capital.

2000000000

0.001

1000000

0.001

10000

<table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">10. </td><td style="vertical-align:top;">Share Purchase Warrants</td></tr><tr style="height:15px"><td> </td><td> The following table summarizes the continuity of the Company’s share purchase warrants:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number ofwarrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted average exercise price$</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,722,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,400,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">53,322,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="vertical-align:top;">As at December 31, 2022, the following share purchase warrants were outstanding:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%"><tbody><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Number of warrants</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">Exercise price </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"> Expiry date</td><td> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"> </td><td style="width:30%;">300,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:30%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:30%;">January 6, 2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 7, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 18, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>300,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 25, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>6,000.000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 27, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>3,400,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 28, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>2,800,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 30, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>872,500</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>February 13, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>350,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>February 20, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>2,500,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 5, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>600,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 7, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>1,000,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 12, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>2,250,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 15, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>5,100,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>July 1, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>500,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>July 19, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>500,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>July 24, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>2,000,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>September 15, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>650,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 19, 2024</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>4,800,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 19, 2024</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,400,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 20, 2024</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>10,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 26, 2024</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 27, 2024</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;">1,000,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 30, 2024</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;">53,322,500</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number ofwarrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted average exercise price$</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58,722,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,400,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">53,322,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

58722500

0.05 -5400000 0.05

53322500

0.05

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%"><tbody><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Number of warrants</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">Exercise price </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"> Expiry date</td><td> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"> </td><td style="width:30%;">300,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:30%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:30%;">January 6, 2023</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 7, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 18, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>300,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 25, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>6,000.000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 27, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>3,400,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 28, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>2,800,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>January 30, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>872,500</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>February 13, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>350,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>February 20, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>2,500,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 5, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>600,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 7, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>1,000,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 12, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>2,250,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>April 15, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>5,100,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>July 1, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>500,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>July 19, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td>500,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>July 24, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td>2,000,000</td><td> </td><td> </td><td>$</td><td class="ffcell">0.05</td><td> </td><td> </td><td>September 15, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>650,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 19, 2024</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>4,800,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 19, 2024</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,400,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 20, 2024</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>10,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 26, 2024</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 27, 2024</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;">1,000,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 30, 2024</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;">53,322,500</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr></tbody></table>

300000 0.05 January 6, 2023 2000000 0.05 January 7, 2023 2000000 0.05 January 18, 2023 300000 0.05 January 25, 2023 6000.000 0.05 January 27, 2023 3400000 0.05 January 28, 2023 2800000 0.05 January 30, 2023 872500 0.05 February 13, 2023 350000 0.05 February 20, 2023 2500000 0.05 April 5, 2023 600000 0.05 April 7, 2023 1000000 0.05 April 12, 2023 2250000 0.05 April 15, 2023 5100000 0.05 July 1, 2023 500000 0.05 July 19, 2023 500000 0.05 July 24, 2023 2000000 0.05 September 15, 2023 650000 0.05 January 19, 2024 4800000 0.05 May 19, 2024 2400000 0.05 May 20, 2024 10000000 0.05 May 26, 2024 2000000 0.05 May 27, 2024 1000000 0.05 May 30, 2024 53322500 <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">11.</td><td style="vertical-align:top;">Memorandum of Understanding </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">On July 25, 2021 the Company entered into a Memorandum of Understanding (“MOU”) to acquire all the assets and cannabis business operation, including 12 acres of property, structure and cannabis licenses, existing sales channels and distribution networks, from a private company situated in Northern California. Upon reaching a definitive agreement, the Company intends to further develop a state- of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and Regional County. The acquisition price is $2,400,000 to be paid through a combination of cash and shares. The Company also has an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. As at December 31, 2022, the Company has advanced $88,850 (September 30, 2022 - $88,850) under the MOU, which will be applied against the final purchase price upon completion of a definitive agreement. This amount has been included in prepaid expenses and deposits. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction. Thus, there is no assurance that the Company will ever enter into, and consummate, a definitive agreement with respect to the contemplated transaction. </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">Subsequent to the three months ended December 31, 2022, the Company terminated the MOU. The advance of $88,850 was converted into a note bearing no interest until September 30, 2025. </td></tr></tbody></table>

2400000

88850

<table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;">12.</td><td colspan="2" style="vertical-align:top;">Commitments and Contingencies </td></tr><tr style="height:15px"><td style="width:4%;vertical-align:top;"> </td><td style="width:4%;vertical-align:top;">(a) </td><td style="vertical-align:top;">Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at December 31, 2022, the Company received advances of $55,342 (Cdn$75,000) (September 30, 2022 - $54,847 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand. </td></tr><tr style="height:15px"><td style="vertical-align:top;"> </td><td style="vertical-align:top;">(b) </td><td style="vertical-align:top;">On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 4(a)). In addition, the Company is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing. </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;"> </td><td style="vertical-align:top;">On March 10, 2021, the noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court. On September 23, 2021, the noteholder filed a new Notice of Motion for Summary Judgement in Lieu of Complaint with the State of New York Supreme Court, County of New York for $44,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. The plaintiff filed for an oral argument which was heard by the State of New York Supreme Court on September 15, 2022 and is pending a final decision. The Company believes that the claim has no merit and intends to defend its position vigorously. </td></tr><tr style="height:15px"><td style="vertical-align:top;"> </td><td style="vertical-align:top;">(c) </td><td style="vertical-align:top;">Effective May 14, 2021, the Company entered into a Software as a Service Agreement with Novation Solutions Inc. (“DealMaker”) to effect the Company’s planned Regulation A offering, including the set-up of an automated tracking, signing, and reconciliation portal. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 30 days prior to launching the portal, and a post launch monthly fee of $1,000. The monthly fee will automatically renew each month for the shorter of the duration of the offering period, or one year.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(d)</td><td style="vertical-align:top;">On May 2, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 7,000,000 shares of common stock in exchange for market awareness services. On May 3, 2022, the Company issued 7,000,000 shares of common stock with a fair value of $84,700 pursuant to the agreement. As at December 31, 2022, the Company recognized $nil (September 30, 2022 - $15,191) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $15,191 (2021 - $nil) pursuant to the agreement.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(e)</td><td style="vertical-align:top;">On May 20, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,000,000 shares of common stock in exchange for public relations and communications services. If both parties agree to continue the agreement for another 6 months, the Company will issue common stock of the Company with a fair value of $80,000. On August 22, 2022, the Company issued 9,000,000 shares of common stock with a fair value of $81,000 pursuant to the agreement. As at December 31, 2022, the Company recognized $nil (September 30, 2022 - $21,481) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $21,481 (2021 - $nil) pursuant to the agreement.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(f)</td><td style="vertical-align:top;">On September 8, 2022, the Company entered into a consulting agreement with a six-month term. Pursuant to the agreement, the Company agreed to issue 9,500,000 shares of common stock in exchange for corporate development, investor, media, public relations, and marketing services. On September 13, 2022, the Company issued 9,500,000 shares of common stock with a fair value of $85,500 pursuant to the agreement. As at December 31, 2022, the Company recognized $31,072 (September 30, 2022 - $75,050) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $43,978 (2021 - $nil) pursuant to the agreement.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(g)</td><td style="vertical-align:top;">On September 15, 2022, the Company entered into a consulting agreement with a twelve-month term. Pursuant to the agreement, the Company agreed to issue 2,500,000 shares of common stock in exchange for management consulting and strategic business advisory services. On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 pursuant to the agreement (Note 8(a)). As at December 31, 2022, the Company recognized $19,419 (September 30, 2022 - $nil) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $6,951 (2021 - $nil) pursuant to the agreement.</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(h)</td><td style="vertical-align:top;">On November 28, 2022, the Company entered into a product endorsement agreement with Tyrell Crosby for an eighteen-month term. Pursuant to the agreement, the Company agreed to issue 10,000,000 shares of common stock in exchange for product endorsement services. On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 pursuant to the agreement (Note 8(b)). As at December 31, 2022, the Company recognized $46,898 (September 30, 2022 - $nil) in prepaid expenses and deposits. During the three months ended December 31, 2022, the Company recognized consulting fees of $3,102 (2021 - $nil) pursuant to the agreement.</td></tr></tbody></table>

The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000.

1018182

1350008 55342 75000 54847 75000

10000000

The purchase price would be 85% of the market price

40000

the Company is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing 40504 0.10 the noteholder filed a new Notice of Motion for Summary Judgement in Lieu of Complaint with the State of New York Supreme Court, County of New York for $44,504 plus interest at the rate of 10% per annum from January 6, 2021, plus costs. The plaintiff filed for an oral argument which was heard by the State of New York Supreme Court on September 15, 2022 and is pending a final decision. The Company believes that the claim has no merit and intends to defend its position vigorously The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 30 days prior to launching the portal, and a post launch monthly fee of $1,000 7000000 the Company issued 7,000,000 shares of common stock with a fair value of $84,700 pursuant to the agreement

84700

15191 15191 the Company agreed to issue 9,000,000 shares of common stock in exchange for public relations and communications services 9000000

80000

81000 21481 21481 the Company agreed to issue 9,500,000 shares of common stock in exchange for corporate development, investor, media, public relations, and marketing services the Company issued 9,500,000 shares of common stock with a fair value of $85,500 pursuant to the agreement 31072 75050 43978 the Company agreed to issue 2,500,000 shares of common stock in exchange for management consulting and strategic business advisory services. On October 3, 2022, the Company issued 2,500,000 shares of common stock with a fair value of $27,500 pursuant to the agreement (Note 8(a))

2500000

19419 6951 the Company agreed to issue 10,000,000 shares of common stock in exchange for product endorsement services. On December 14, 2022, the Company issued 10,000,000 shares of common stock with a fair value of $50,000 pursuant to the agreement (Note 8(b)) 46898 3102

88850 17672500

0.05

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 179 201 1 false 61 0 false 5 false false R1.htm 000001 - Document - Cover Sheet http://phbi.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Consolidated Financial Statements Sheet http://phbi.com/role/CondensedConsolidatedFinancialStatements Condensed Consolidated Financial Statements Statements 2 false false R3.htm 000003 - Statement - Condensed Consolidated Financial Statements (Parenthetical) Sheet http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical Condensed Consolidated Financial Statements (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Nature of Business and Continuance of Operations Sheet http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations Nature of Business and Continuance of Operations Notes 7 false false R8.htm 000008 - Disclosure - Significant Accounting Policies Sheet http://phbi.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://phbi.com/role/AccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 9 false false R10.htm 000010 - Disclosure - Loans Payable Sheet http://phbi.com/role/LoansPayable Loans Payable Notes 10 false false R11.htm 000011 - Disclosure - Convertible Notes Notes http://phbi.com/role/ConvertibleNotes Convertible Notes Notes 11 false false R12.htm 000012 - Disclosure - Derivative Liabilities Sheet http://phbi.com/role/DerivativeLiabilities Derivative Liabilities Notes 12 false false R13.htm 000013 - Disclosure - Related Party Transactions Sheet http://phbi.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 000014 - Disclosure - Common Stock Sheet http://phbi.com/role/CommonStock Common Stock Notes 14 false false R15.htm 000015 - Disclosure - Preferred Stock Sheet http://phbi.com/role/PreferredStock Preferred Stock Notes 15 false false R16.htm 000016 - Disclosure - Share Purchase Warrants Sheet http://phbi.com/role/SharePurchaseWarrants Share Purchase Warrants Notes 16 false false R17.htm 000017 - Disclosure - Memorandum of Understanding Sheet http://phbi.com/role/MemorandumOfUnderstanding Memorandum of Understanding Notes 17 false false R18.htm 000018 - Disclosure - Commitments and Contigency Sheet http://phbi.com/role/CommitmentsAndContigency Commitments and Contigency Notes 18 false false R19.htm 000019 - Disclosure - Subsequent Events Sheet http://phbi.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 000020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://phbi.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://phbi.com/role/SignificantAccountingPolicies 20 false false R21.htm 000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://phbi.com/role/AccountsPayableAndAccruedLiabilities 21 false false R22.htm 000022 - Disclosure - Derivative Liabilities (Tables) Sheet http://phbi.com/role/DerivativeLiabilitiesTables Derivative Liabilities (Tables) Tables http://phbi.com/role/DerivativeLiabilities 22 false false R23.htm 000023 - Disclosure - Share Purchase Warrants (Tables) Sheet http://phbi.com/role/SharePurchaseWarrantsTables Share Purchase Warrants (Tables) Tables http://phbi.com/role/SharePurchaseWarrants 23 false false R24.htm 000024 - Disclosure - Nature of Business and Continuance of Operations (Details Narrative) Sheet http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative Nature of Business and Continuance of Operations (Details Narrative) Details http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations 24 false false R25.htm 000025 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables 25 false false R26.htm 000026 - Disclosure - Loans Payable (Details Narrative) Sheet http://phbi.com/role/LoansPayableDetailsNarrative Loans Payable (Details Narrative) Details http://phbi.com/role/LoansPayable 26 false false R27.htm 000027 - Disclosure - Convertible Notes (Details Narrative) Notes http://phbi.com/role/ConvertibleNotesDetailsNarrative Convertible Notes (Details Narrative) Details http://phbi.com/role/ConvertibleNotes 27 false false R28.htm 000028 - Disclosure - Derivative Liabilities (Details) Sheet http://phbi.com/role/DerivativeLiabilitiesDetails Derivative Liabilities (Details) Details http://phbi.com/role/DerivativeLiabilitiesTables 28 false false R29.htm 000029 - Disclosure - Derivative Liabilities (Details 1) Sheet http://phbi.com/role/DerivativeLiabilitiesDetails1 Derivative Liabilities (Details 1) Details http://phbi.com/role/DerivativeLiabilitiesTables 29 false false R30.htm 000030 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://phbi.com/role/RelatedPartyTransactions 30 false false R31.htm 000031 - Disclosure - Common Stock (Details Narrative) Sheet http://phbi.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://phbi.com/role/CommonStock 31 false false R32.htm 000032 - Disclosure - Preferred Stock (Details Narrative) Sheet http://phbi.com/role/PreferredStockDetailsNarrative Preferred Stock (Details Narrative) Details http://phbi.com/role/PreferredStock 32 false false R33.htm 000033 - Disclosure - Share Purchase Warrants (Details) Sheet http://phbi.com/role/SharePurchaseWarrantsDetails Share Purchase Warrants (Details) Details http://phbi.com/role/SharePurchaseWarrantsTables 33 false false R34.htm 000034 - Disclosure - Share Purchase Warrants (Details 1) Sheet http://phbi.com/role/SharePurchaseWarrantsDetails1 Share Purchase Warrants (Details 1) Details http://phbi.com/role/SharePurchaseWarrantsTables 34 false false R35.htm 000035 - Disclosure - Memorandum of Understanding (Details Narrative) Sheet http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative Memorandum of Understanding (Details Narrative) Details http://phbi.com/role/MemorandumOfUnderstanding 35 false false R36.htm 000036 - Disclosure - Commitments and Contigency (Details Narrative) Sheet http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative Commitments and Contigency (Details Narrative) Details http://phbi.com/role/CommitmentsAndContigency 36 false false R37.htm 000037 - Disclosure - Subsequent Events (Details Narrative) Sheet http://phbi.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://phbi.com/role/SubsequentEvents 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 23 fact(s) appearing in ix:hidden were eligible for transformation: phbi:ConsultingFee, phbi:ConsultingFees, phbi:MaximunSharesPurchaseUnderAgreement, phbi:PrepaidExpensesAndDepositsAmount, us-gaap:AccretionExpense, us-gaap:AmortizationOfDebtDiscountPremium, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:ConvertibleNotesPayable, us-gaap:DerivativeFairValueOfDerivativeLiability, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding - phbi_10q.htm 1 phbi_10q.htm phbi-20221231.xsd phbi-20221231_cal.xml phbi-20221231_def.xml phbi-20221231_lab.xml phbi-20221231_pre.xml phbi_ex311.htm phbi_ex321.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "phbi_10q.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 361, "http://xbrl.sec.gov/dei/2022": 26 }, "contextCount": 179, "dts": { "calculationLink": { "local": [ "phbi-20221231_cal.xml" ] }, "definitionLink": { "local": [ "phbi-20221231_def.xml" ] }, "inline": { "local": [ "phbi_10q.htm" ] }, "labelLink": { "local": [ "phbi-20221231_lab.xml" ] }, "presentationLink": { "local": [ "phbi-20221231_pre.xml" ] }, "schema": { "local": [ "phbi-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 316, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 14, "http://phbi.com/20221231": 9, "http://xbrl.sec.gov/dei/2022": 5, "total": 28 }, "keyCustom": 55, "keyStandard": 146, "memberCustom": 54, "memberStandard": 7, "nsprefix": "phbi", "nsuri": "http://phbi.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://phbi.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:LoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Loans Payable", "menuCat": "Notes", "order": "10", "role": "http://phbi.com/role/LoansPayable", "shortName": "Loans Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:LoansPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Convertible Notes", "menuCat": "Notes", "order": "11", "role": "http://phbi.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Derivative Liabilities", "menuCat": "Notes", "order": "12", "role": "http://phbi.com/role/DerivativeLiabilities", "shortName": "Derivative Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "13", "role": "http://phbi.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Common Stock", "menuCat": "Notes", "order": "14", "role": "http://phbi.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Preferred Stock", "menuCat": "Notes", "order": "15", "role": "http://phbi.com/role/PreferredStock", "shortName": "Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:SharePurchaseWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Share Purchase Warrants", "menuCat": "Notes", "order": "16", "role": "http://phbi.com/role/SharePurchaseWarrants", "shortName": "Share Purchase Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:SharePurchaseWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:MemorandumOfUnderstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Memorandum of Understanding", "menuCat": "Notes", "order": "17", "role": "http://phbi.com/role/MemorandumOfUnderstanding", "shortName": "Memorandum of Understanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:MemorandumOfUnderstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Commitments and Contigency", "menuCat": "Notes", "order": "18", "role": "http://phbi.com/role/CommitmentsAndContigency", "shortName": "Commitments and Contigency", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "19", "role": "http://phbi.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Condensed Consolidated Financial Statements", "menuCat": "Statements", "order": "2", "role": "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "shortName": "Condensed Consolidated Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:InterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "20", "role": "http://phbi.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:InterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "menuCat": "Tables", "order": "21", "role": "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Derivative Liabilities (Tables)", "menuCat": "Tables", "order": "22", "role": "http://phbi.com/role/DerivativeLiabilitiesTables", "shortName": "Derivative Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:ScheduleOfSharePurchaseWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Share Purchase Warrants (Tables)", "menuCat": "Tables", "order": "23", "role": "http://phbi.com/role/SharePurchaseWarrantsTables", "shortName": "Share Purchase Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:ScheduleOfSharePurchaseWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Nature of Business and Continuance of Operations (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative", "shortName": "Nature of Business and Continuance of Operations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "menuCat": "Details", "order": "25", "role": "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-01-01to2020-01-14", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Loans Payable (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://phbi.com/role/LoansPayableDetailsNarrative", "shortName": "Loans Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-01-01to2020-01-14", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Convertible Notes (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "shortName": "Convertible Notes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfDebtDiscountPremium", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Derivative Liabilities (Details)", "menuCat": "Details", "order": "28", "role": "http://phbi.com/role/DerivativeLiabilitiesDetails", "shortName": "Derivative Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "lang": null, "name": "phbi:ChangeInFairValueOfEmbeddedConversionOption", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfPriceRiskDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31_phbi_DerivativeLiabilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Derivative Liabilities (Details 1)", "menuCat": "Details", "order": "29", "role": "http://phbi.com/role/DerivativeLiabilitiesDetails1", "shortName": "Derivative Liabilities (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfPriceRiskDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31_phbi_DerivativeLiabilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleSubordinatedDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Condensed Consolidated Financial Statements (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical", "shortName": "Condensed Consolidated Financial Statements (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleSubordinatedDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31_srt_PresidentMember", "decimals": "0", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Common Stock (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://phbi.com/role/CommonStockDetailsNarrative", "shortName": "Common Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31_phbi_OctoberTwentyOneTwoThousandTwentyOneMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Preferred Stock (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://phbi.com/role/PreferredStockDetailsNarrative", "shortName": "Preferred Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-10-13", "decimals": "0", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "phbi:ScheduleOfSharePurchaseWarrantsTableTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-09-30_phbi_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Share Purchase Warrants (Details)", "menuCat": "Details", "order": "33", "role": "http://phbi.com/role/SharePurchaseWarrantsDetails", "shortName": "Share Purchase Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "phbi:ScheduleOfSharePurchaseWarrantsTableTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-09-30_phbi_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:NumberOfWarrants2E", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Share Purchase Warrants (Details 1)", "menuCat": "Details", "order": "34", "role": "http://phbi.com/role/SharePurchaseWarrantsDetails1", "shortName": "Share Purchase Warrants (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:NumberOfWarrants2E", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "phbi:MemorandumOfUnderstandingTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31_phbi_MOUMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Memorandum of Understanding (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative", "shortName": "Memorandum of Understanding (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "phbi:MemorandumOfUnderstandingTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2022-12-31_phbi_MOUMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-03-10", "decimals": "0", "first": true, "lang": null, "name": "phbi:LieuOfComplaintAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Commitments and Contigency (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "shortName": "Commitments and Contigency (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-03-10", "decimals": "0", "first": true, "lang": null, "name": "phbi:LieuOfComplaintAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:DebtInstrumentNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://phbi.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:DebtInstrumentNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "phbi:ConsultingFees", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Nature of Business and Continuance of Operations", "menuCat": "Notes", "order": "7", "role": "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations", "shortName": "Nature of Business and Continuance of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://phbi.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Accounts Payable and Accrued Liabilities", "menuCat": "Notes", "order": "9", "role": "http://phbi.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2022-10-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 61, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "phbi_AccretionOfDiscountOnConvertibleNotes": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accretion of discount on convertible notes" } } }, "localname": "AccretionOfDiscountOnConvertibleNotes", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_AdditionalCommitmentFeeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional commitment fee description" } } }, "localname": "AdditionalCommitmentFeeDescription", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_AdvancesFromAllianceGrowersCorp": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances from Alliance Growers Corp. (Note 12(a))", "verboseLabel": "Advances from Alliance Growers Corp" } } }, "localname": "AdvancesFromAllianceGrowersCorp", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "phbi_AgreementDescriptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement descriptions" } } }, "localname": "AgreementDescriptions", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_AllianceGrowersCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alliance Growers Corp. [Member]" } } }, "localname": "AllianceGrowersCorpMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_CAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "verboseLabel": "CANADA" } } }, "localname": "CAMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ChangeInFairValueOfEmbeddedConversionOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of embedded conversion option" } } }, "localname": "ChangeInFairValueOfEmbeddedConversionOption", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "phbi_ClassOfWarrantOrRightExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Expired" } } }, "localname": "ClassOfWarrantOrRightExpired", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_CommonStockIssuable": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issuable" } } }, "localname": "CommonStockIssuable", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "phbi_CommonStockIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issuable" } } }, "localname": "CommonStockIssuableMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "phbi_CommonStockSharesIssuedConsultingServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued consulting services" } } }, "localname": "CommonStockSharesIssuedConsultingServices", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_CommonStockSharesIssuedFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock shares issued Fair value" } } }, "localname": "CommonStockSharesIssuedFairValue", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_CommonStockSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares of common stock received" } } }, "localname": "CommonStockSharesReceived", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_CompanyControllerByChiefFinancialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Company Controller By Chief Financial Officer [Member]" } } }, "localname": "CompanyControllerByChiefFinancialOfficerMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement May 20, 2022 [Member]" } } }, "localname": "ConsultingAgreementMayTwentyTwoThousandTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingAgreementMayTwoTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement May 2, 2022 [Member]" } } }, "localname": "ConsultingAgreementMayTwoTwoThousandTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement November 28, 2022 [Member]" } } }, "localname": "ConsultingAgreementNovemberTwoEightTwentyTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingAgreementSeptemberEightTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement Sep 8, 2022 [Member]" } } }, "localname": "ConsultingAgreementSeptemberEightTwentyTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement Sep 15, 2022 [Member]" } } }, "localname": "ConsultingAgreementSeptemberFifteenTwentyTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Consulting Fee]", "verboseLabel": "Consulting Fee" } } }, "localname": "ConsultingFee", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_ConsultingFees": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting Fees", "label": "Consulting fees (Note 7 and 12)", "verboseLabel": "Consulting Fee" } } }, "localname": "ConsultingFees", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_ConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note [Member]" } } }, "localname": "ConvertibleNoteMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes" } } }, "localname": "ConvertibleNotesAbstract", "nsuri": "http://phbi.com/20221231", "xbrltype": "stringItemType" }, "phbi_ConvertibleNotesPayable1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Convertible note payable]", "verboseLabel": "Convertible note payable" } } }, "localname": "ConvertibleNotesPayable1", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DebtInstrumentNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible promissory note" } } }, "localname": "DebtInstrumentNoncurrent", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DecemberFourteenTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 14, 2022" } } }, "localname": "DecemberFourteenTwoThousandTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_DerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability [Member]" } } }, "localname": "DerivativeLiabilityMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "phbi_DescriptionOfConversionOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of conversion of convertible notes" } } }, "localname": "DescriptionOfConversionOfConvertibleNotes", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_DirectlyPaidToThirdPartyForFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Directly paid to third party for financing" } } }, "localname": "DirectlyPaidToThirdPartyForFinancing", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DueDateOfNote": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Due date of note", "verboseLabel": "Due date of note" } } }, "localname": "DueDateOfNote", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_EarningPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted (loss) income per share attributable to Pharmagreen Biotech Inc. stockholders" } } }, "localname": "EarningPerShareBasicAndDiluted", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "phbi_EquityPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Purchase Agreement [Member]" } } }, "localname": "EquityPurchaseAgreementMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "localname": "ExercisePrice", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "perShareItemType" }, "phbi_ExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiry date" } } }, "localname": "ExpiryDate", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "phbi_FairValueOfcommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock fair value" } } }, "localname": "FairValueOfcommonStock", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_FatherOfPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Father of President [Member]" } } }, "localname": "FatherOfPresidentMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FatherOfPresidentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Father of President One [Member]" } } }, "localname": "FatherOfPresidentOneMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FatherOfPresidentThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Father of President Three [Member]" } } }, "localname": "FatherOfPresidentThreeMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FatherOfPresidentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Father of President Two [Member]" } } }, "localname": "FatherOfPresidentTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_IncreasedRateOfInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increased Rate of interest" } } }, "localname": "IncreasedRateOfInterest", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "phbi_IncurrenceConsultingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting Fees" } } }, "localname": "IncurrenceConsultingFees", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_InterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Interest rate]", "verboseLabel": "Interest rate" } } }, "localname": "InterestRate", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "phbi_InterimFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interim Financial Statements" } } }, "localname": "InterimFinancialStatementsPolicyTextBlock", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "phbi_JanuaryTwentyTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 22, 2020 [Member]" } } }, "localname": "JanuaryTwentyTwoThousandTwentyMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LieuOfComplaintAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Lieu of Complaint notice amount" } } }, "localname": "LieuOfComplaintAmount", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_LieuOfComplaintInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lieu of Complaint notice Interest rate" } } }, "localname": "LieuOfComplaintInterestRate", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "percentItemType" }, "phbi_LieuOfComplaintNoticeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lieu of Complaint notice Description" } } }, "localname": "LieuOfComplaintNoticeDescription", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_LoanForgivenessDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan forgiveness description" } } }, "localname": "LoanForgivenessDescription", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_LoanPayableAprilTwentyTwoTwentyThousandyTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Loan Payable April 22, 2020 [Member]]", "verboseLabel": "Loan Payable April 22, 2020 [Member]" } } }, "localname": "LoanPayableAprilTwentyTwoTwentyThousandyTwentyMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LoanReceivable1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loan Receivable" } } }, "localname": "LoanReceivable1", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_LoansPayable1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Nov. 22, 2019 [Member]" } } }, "localname": "LoansPayable1Member", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LoansPayable2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable April 22, 2020 [Member]" } } }, "localname": "LoansPayable2Member", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LoansPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Loans Payable 1]", "verboseLabel": "Loans Payable" } } }, "localname": "LoansPayableTextBlock", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayable" ], "xbrltype": "textBlockItemType" }, "phbi_MOUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M O U [Member]" } } }, "localname": "MOUMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_MarchElevenTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 11 2022 [Member]" } } }, "localname": "MarchElevenTwentyTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_MaximumIntrinsicValueOfTheEmbeddedBeneficialConversionFeature": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Maximum intrinsic value of the embedded beneficial conversion feature" } } }, "localname": "MaximumIntrinsicValueOfTheEmbeddedBeneficialConversionFeature", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_MaximunSharesPurchaseUnderAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximun shares purchase under agreement" } } }, "localname": "MaximunSharesPurchaseUnderAgreement", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_MemorandumOfUnderstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Memorandum of Understanding" } } }, "localname": "MemorandumOfUnderstandingAbstract", "nsuri": "http://phbi.com/20221231", "xbrltype": "stringItemType" }, "phbi_MemorandumOfUnderstandingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Memorandum of Understanding]", "verboseLabel": "Memorandum of Understanding" } } }, "localname": "MemorandumOfUnderstandingTextBlock", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/MemorandumOfUnderstanding" ], "xbrltype": "textBlockItemType" }, "phbi_NovationSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Novation Solutions Inc [Member]" } } }, "localname": "NovationSolutionsIncMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NovemberSecondTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2, 2022 [Member]" } } }, "localname": "NovemberSecondTwoThousandTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NumberOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of warrants" } } }, "localname": "NumberOfWarrants", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "sharesItemType" }, "phbi_NumberOfWarrants2E": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Number of warrants]", "verboseLabel": "Number of warrants" } } }, "localname": "NumberOfWarrants2E", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "sharesItemType" }, "phbi_OctoberThreeTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 3, 2022 [Member]" } } }, "localname": "OctoberThreeTwoThousandTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_OctoberTwentyOneTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 21, 2021 [Member]" } } }, "localname": "OctoberTwentyOneTwoThousandTwentyOneMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_OptionAgreementGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option agreement grants" } } }, "localname": "OptionAgreementGrants", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_PreferredStockDesignated": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock designated" } } }, "localname": "PreferredStockDesignated", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_PreferredStocksOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stocks [Member]" } } }, "localname": "PreferredStocksOneMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_PrepaidExpensesAndDepositsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Prepaid expenses and deposits]", "verboseLabel": "Prepaid expenses and deposits" } } }, "localname": "PrepaidExpensesAndDepositsAmount", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_PurchasePriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase price description" } } }, "localname": "PurchasePriceDescription", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_RateOfInterestOnUnpaidBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rate of interest", "verboseLabel": "Rate of interest" } } }, "localname": "RateOfInterestOnUnpaidBalance", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "phbi_RateOfInterestOnUnpaidBalanceAfterDefaultOfNote": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rate of interest on unpaid balance after default of note" } } }, "localname": "RateOfInterestOnUnpaidBalanceAfterDefaultOfNote", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "phbi_RateOfStringentPrePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rate of stringent pre-payment" } } }, "localname": "RateOfStringentPrePayment", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "phbi_ReducedCarryingValueOfConvertibleNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Reduced carrying value of convertible note" } } }, "localname": "ReducedCarryingValueOfConvertibleNote", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_ScheduleOfSharePurchaseWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Share Purchase Warrants" } } }, "localname": "ScheduleOfSharePurchaseWarrantsTableTextBlock", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsTables" ], "xbrltype": "textBlockItemType" }, "phbi_SeriesASuperVotingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Super Voting Preferred Stock [Member]" } } }, "localname": "SeriesASuperVotingPreferredStockMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ServiceAgreementFeePayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Service agreement fee payable description" } } }, "localname": "ServiceAgreementFeePayableDescription", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsExpired", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "sharesItemType" }, "phbi_SharePurchaseWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Purchase Warrants" } } }, "localname": "SharePurchaseWarrantsAbstract", "nsuri": "http://phbi.com/20221231", "xbrltype": "stringItemType" }, "phbi_SharePurchaseWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Purchase Warrant [Text block]", "label": "[Share Purchase Warrants]", "verboseLabel": "Share Purchase Warrants" } } }, "localname": "SharePurchaseWarrantsTextBlock", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrants" ], "xbrltype": "textBlockItemType" }, "phbi_StockIssuedDuringPeriodValueConversionOfUnit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common Stock Issued upon exercise of the option, value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnit", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_StockIssuedDuringPeriodValuesIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, amount" } } }, "localname": "StockIssuedDuringPeriodValuesIssuedForServices", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_UnrelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrelated party [Member]" } } }, "localname": "UnrelatedPartyMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_WarrantsEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Eight [Member]" } } }, "localname": "WarrantsEightMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Eighteen [Member]" } } }, "localname": "WarrantsEighteenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Eleven [Member]" } } }, "localname": "WarrantsElevenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Fifteen [Member]" } } }, "localname": "WarrantsFifteenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Five [Member]" } } }, "localname": "WarrantsFiveMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Four [Member]" } } }, "localname": "WarrantsFourMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsFourteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Fourteen [Member]" } } }, "localname": "WarrantsFourteenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "domainItemType" }, "phbi_WarrantsNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Nine [Member]" } } }, "localname": "WarrantsNineMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Nineteen [Member]" } } }, "localname": "WarrantsNineteenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant One [Member]" } } }, "localname": "WarrantsOneMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Seven [Member]" } } }, "localname": "WarrantsSevenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Seventeen [Member]" } } }, "localname": "WarrantsSeventeenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Six [Member]" } } }, "localname": "WarrantsSixMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsSixteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Sixteen [Member]" } } }, "localname": "WarrantsSixteenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Ten [Member]" } } }, "localname": "WarrantsTenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsThirteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Thirteen [Member]" } } }, "localname": "WarrantsThirteenMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Three [Member]" } } }, "localname": "WarrantsThreeMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Twelve [Member]" } } }, "localname": "WarrantsTwelveMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Twenty [Member]" } } }, "localname": "WarrantsTwentyMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Twenty One [Member]" } } }, "localname": "WarrantsTwentyOneMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Twenty Three [Member]" } } }, "localname": "WarrantsTwentyThreeMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Twenty Two [Member]" } } }, "localname": "WarrantsTwentyTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Two [Member]" } } }, "localname": "WarrantsTwoMember", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WeightedAverageExercisePriceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price, beginning]", "periodStartLabel": "Weighted average exercise price, beginning" } } }, "localname": "WeightedAverageExercisePriceBeginning", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "perShareItemType" }, "phbi_WeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price, ending]", "periodEndLabel": "Weighted average exercise price, ending" } } }, "localname": "WeightedAverageExercisePriceEnding", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "perShareItemType" }, "phbi_WeightedAverageExercisePriceExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price,Expired" } } }, "localname": "WeightedAverageExercisePriceExpired", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "perShareItemType" }, "phbi_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding used in the calculation of net (loss) income per share attributable to Pharmagreen Biotech Inc." } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" }, "phbi_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Working Capital Deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://phbi.com/20221231", "presentation": [ "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "srt_PresidentMember": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r163", "r164", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r344", "r350", "r380" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r163", "r164", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r344", "r350", "r380" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities (Notes 3 and 7)", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r9", "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableInterestBearingCurrent": { "auth_ref": [ "r9", "r76", "r77", "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to vendors that bear interest at either a stated or an imputed rate. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest payable" } } }, "localname": "AccountsPayableInterestBearingCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r165", "r166" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Amounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r42" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion of discount on convertible notes (Note 5)" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r341", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r24", "r25", "r110", "r315", "r321", "r322" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r22", "r25", "r68", "r261", "r317", "r318", "r358", "r359", "r360", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r81", "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition price" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r4", "r349" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital (Note 8)" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r230", "r231", "r232", "r366", "r367", "r368", "r407" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r32", "r41", "r76", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Unamortized discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r83", "r91", "r106", "r130", "r157", "r159", "r161", "r169", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r237", "r241", "r249", "r349", "r377", "r378", "r412" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r235", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r63", "r64", "r235", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition Axis" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r323", "r324", "r349", "r356" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r38", "r43", "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r38", "r74" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect]", "totalLabel": "Change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r107", "r108", "r109", "r130", "r143", "r144", "r146", "r147", "r149", "r150", "r169", "r181", "r184", "r185", "r186", "r190", "r191", "r206", "r207", "r209", "r213", "r220", "r249", "r336", "r355", "r363", "r369" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "[Class of Warrant or Right, Exercise Price of Warrants or Rights]", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contigency" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r53", "r179", "r180", "r326", "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contigency" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigency" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r366", "r367", "r407" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par Value", "terseLabel": "Common Stock, Par Value", "verboseLabel": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued", "verboseLabel": "Number of common share issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r56" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r349" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 454,760,969 and 442,260,969 shares issued and outstanding, respectively (Note 8)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r26", "r115", "r117", "r121", "r313", "r316" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "[Comprehensive Income (Loss), Net of Tax, Attributable to Parent]", "totalLabel": "Comprehensive (loss) income attributable to Pharmagreen Biotech Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r0" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible note debt", "verboseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r1", "r85", "r93", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible note payable", "verboseLabel": "Carrying value of convertible notes" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes - current portion, net of unamortized discount of $9,859 and $15,780, respectively (Note 5)" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleSubordinatedDebtCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of convertible subordinated debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. This form of debt can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder, and places a lender in a lien position behind debt having a higher priority of repayment upon liquidation of the entity's assets.", "label": "Convertible Notes, Unamortized Discount, Current" } } }, "localname": "ConvertibleSubordinatedDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion By Unique Description Axis" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r55", "r128", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r77", "r79", "r192", "r260", "r342", "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face value of convertible notes" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r76", "r79", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Remaining debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r20", "r71", "r80", "r111", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Fair value of the derivative liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r73", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r112", "r113", "r248", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r112" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities (Notes 5 and 6)", "periodEndLabel": "Derivative Liability, ending", "periodStartLabel": "Derivative Liability, beginning" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Loss on change in fair value of derivative" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r9", "r183", "r184", "r185", "r189", "r190", "r191", "r265", "r365" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related parties (Note 7)", "verboseLabel": "Due to Related Parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r17", "r183", "r184", "r185", "r189", "r190", "r191", "r265", "r365" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Loans payable to related parties (Note 7)", "verboseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r409" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r56", "r102", "r118", "r119", "r120", "r131", "r132", "r133", "r135", "r140", "r142", "r148", "r170", "r222", "r230", "r231", "r232", "r233", "r234", "r246", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r167", "r168", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r204", "r218", "r244", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r340", "r371", "r372", "r373", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument Axis" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r250", "r251", "r252", "r253" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "[Foreign Currency Transaction Gain (Loss), before Tax]", "negatedLabel": "Foreign exchange (gain) loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r41", "r89" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 9.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain on change in fair value of derivative liabilities (Note 6)", "negatedLabel": "Gain on change in fair value of derivative liabilities" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r28", "r120" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 15.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "[Income (Loss) Attributable to Parent, before Tax]", "totalLabel": "Net (loss) income attributable to Pharmagreen Biotech Inc." } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r40" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "[Increase (Decrease) in Accounts Receivable]", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r40" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in non-cash operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]", "negatedLabel": "Prepaid expenses and deposits" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDebtExpense": { "auth_ref": [ "r75" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.", "label": "[Interest and Debt Expense]", "negatedLabel": "Interest and finance costs (Note 4 and 5)" } } }, "localname": "InterestAndDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendsPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accured Interest Payable" } } }, "localname": "InterestAndDividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r122", "r125", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r41" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Common stock issued or issuable for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r130", "r169", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r238", "r241", "r242", "r249", "r338", "r377", "r412", "r413" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r8", "r87", "r97", "r349", "r364", "r374", "r408" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r105", "r130", "r169", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r238", "r241", "r242", "r249", "r349", "r377", "r412", "r413" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r1", "r85", "r90" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "[Loans Payable]", "verboseLabel": "Loans payable (Note 4)" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loans Payable" } } }, "localname": "LoansPayableAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans payable (Note 4)", "verboseLabel": "Loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type Axis" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r16", "r54" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r19", "r86", "r96", "r130", "r169", "r181", "r184", "r185", "r186", "r190", "r191", "r249" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r151", "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "verboseLabel": "Nature of Business and Continuance of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r124" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r38", "r39", "r42" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities", "verboseLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r42", "r88", "r98", "r104", "r114", "r116", "r120", "r130", "r134", "r136", "r137", "r138", "r139", "r141", "r142", "r145", "r157", "r158", "r160", "r162", "r169", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r247", "r249", "r339", "r377" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 13.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net (loss) income", "verboseLabel": "Net income for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r67", "r70", "r114", "r116", "r141", "r142", "r360" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 14.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Less: net loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r65", "r222", "r366", "r367", "r368" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Non-controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r157", "r158", "r160", "r162", "r339" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Net loss before other income (expenses)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Continuance of Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r21" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 16.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation loss", "verboseLabel": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLoansPayable": { "auth_ref": [ "r1", "r85", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans payable classified as other.", "label": "Loans payable" } } }, "localname": "OtherLoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r33" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Total other income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "verboseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r2", "r206" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par Value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r2", "r206" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Issuance Of preferred stock, shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatementsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "Preferred Stock [Text Block]", "verboseLabel": "Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/PreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r2", "r349" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 shares issued and outstanding (Note 9)", "verboseLabel": "Issuance Of preferred stock, value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r357" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and deposits (Notes 11 and 12)" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r35" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from issuance of convertible note" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r34" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of shares", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from convertible debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r35" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from loans from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r100", "r101" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r104", "r114", "r116", "r123", "r130", "r134", "r141", "r142", "r157", "r158", "r160", "r162", "r169", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r236", "r239", "r240", "r247", "r249", "r314", "r339", "r347", "r348", "r360", "r377" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net (loss) income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Amount advanced" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecoveryStrandedCosts": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue from billings to utility customers to recover what are also referred to as stranded assets or stranded investments. These are assets that formerly regulated utilities with monopolies on local service are allowed to recover during their transition to deregulated suppliers in competitive markets. Essentially, these investments are sunk costs, made by utilities under the old regulated system, which might not be recovered in a truly competitive marketplace. However, since they were valid investments at the time, the utilities are allowed to recover these costs from customers (for example, an investment in electrical generation assets that may not be recouped if customers are now allowed to purchase electricity from another utility).", "label": "Recovery of default penalties" } } }, "localname": "RecoveryStrandedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r223", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r183", "r184", "r185", "r189", "r190", "r191", "r365", "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Amount Owed to Related Party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r223", "r264", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r262", "r263", "r265", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r36" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "[Repayments of Related Party Debt]", "negatedLabel": "Repayment of loans from related parties" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r5", "r59", "r95", "r320", "r322", "r349" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r102", "r131", "r132", "r133", "r135", "r140", "r142", "r170", "r230", "r231", "r232", "r233", "r234", "r246", "r317", "r319" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Default penalty" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r361" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and wages" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liability" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPriceRiskDerivativesTableTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of price risk derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of analytical assumptions of derivatives" } } }, "localname": "ScheduleOfPriceRiskDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r60", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r0", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Promissory Note with unrelated party", "verboseLabel": "Promissory Note with unrelated party" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Common stock shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Interest rate" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r107", "r108", "r109", "r130", "r143", "r144", "r146", "r147", "r149", "r150", "r169", "r181", "r184", "r185", "r186", "r190", "r191", "r206", "r207", "r209", "r213", "r220", "r249", "r336", "r355", "r363", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock Axis" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r56", "r102", "r118", "r119", "r120", "r131", "r132", "r133", "r135", "r140", "r142", "r148", "r170", "r222", "r230", "r231", "r232", "r233", "r234", "r246", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/DerivativeLiabilitiesDetails1", "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Financial Statements" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r131", "r132", "r133", "r148", "r300" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative", "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/DerivativeLiabilitiesDetails1", "http://phbi.com/role/LoansPayableDetailsNarrative", "http://phbi.com/role/MemorandumOfUnderstandingDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r2", "r3", "r56", "r57", "r59" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common Stock Issued upon exercise of the option (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Issuance of common stock for services, shares", "verboseLabel": "Common stock shares issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r2", "r3", "r56", "r59" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of units for cash, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r18", "r56", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Option consideration" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommitmentsAndContigencyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock shares issued for services, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r2", "r3", "r56", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of units for cash, amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r6", "r7", "r52", "r349", "r364", "r374", "r408" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "totalLabel": "Total Pharmagreen Biotech Inc. stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r66", "r69", "r102", "r103", "r119", "r131", "r132", "r133", "r135", "r140", "r170", "r222", "r230", "r231", "r232", "r233", "r234", "r246", "r254", "r255", "r259", "r261", "r318", "r319", "r364", "r374", "r408" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedFinancialStatements": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "[Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedFinancialStatements", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r61", "r129", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r222", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r167", "r168", "r204", "r218", "r244", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r371", "r372", "r373", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r49", "r50", "r51", "r152", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates and Judgments" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://phbi.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r352": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r353": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r354": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 54 0001477932-23-000992-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-000992-xbrl.zip M4$L#!!0 ( &)Z3E; 2LC%W0\ !RJ 1 <&AB:2TR,#(R,3(S,2YX M=7[H%SG& ,?^1P.)29CS^][GSG&3-. GH^F1\=3QQ, MW< C=',^"?D4<9>0B<,%HA[R XK/)P?,)S_]^,]_?/S7=/K;Q<,GYRIPPQVF MPKED& GL.2]$;!U)^HRXP&PZC;E_B=HY7R .4@%5,D"<)Y0K MT.<$:\>5FI7H\@[5X00P[B+E;(K K0H9\Q\.<;*@#ACN1 M0V?.XAO7N=HBMD-[AG>(2J>=V>G?]Y%R$ MG%#,N?,8^*$TA?_;N:7ND;/P?>=!2G#G 7/,GK$7J^/N%AIQH(;8+GF:;*OCK1(H#H!J']% F12*T17RG],7$&1$96H0"<8S%.7',C0,CI MQZ_NULPI*3E60I\Q%V;FB ;L\]/I\7QZ.M="%&_D"*OLGP\S%OAX%K,E4HBX MW-R2(A6[2!SVF!O[1U%R[%SL647? "7+FC/ZY52;/)_]]OG3HQHJDV2LP' P ML<\_?/@P4U3-6N+,#RQ)7L'L2C0#E=3P$RIGNIOC]PH@Q24Q3Z6BTF.(4,6 MB&VPN$,[S/?(Q36-00AVG(^(TD"HM4-]ET_V>T+70?P5'LA)H)^*GNN.Z]B?U, 7%\($' M/O%DW+XAL#*[!/F/X+0:#5QW>4-N*RHG $7"KV")-3M9U4ZB.V7F(WAMP;N' MY(R*+18$?&J'9%[4"NMI=UB==[FVOAUAKH4Y[;CE>KG'3#G %Q28=M 96Q @ MS_A3P/D7BD*/J'2L$ODNVJR#X;MF@R$S!&"GD;:N=@ZY]AUI@/,N,6$<(\W' MR*,(W#^V@>_!'A#6=>(2T79@U*JPCH;ONXR&;)/?.'&CXPCH- (N$=_>^,%+ MZX!@$+2B_;X+VK(A1[4T0FR"^ Z)D.'E6M="5'RF@M!0[AFSD3M"M@6_%=#_ MR#2:<-!P&E)(/_4VM_S8G]G5#A*Q]CGNL^O,"//8"#LO8KQQTRR]OY) ML?=3/6-X,4'P@'V9JMXC)@Y/#"(#8,;D)3/JY\,S:U=\7NSI1,/9V M83>P10S?A\S=(HY_10SFO2ZWFTG6OG]?ROZE'D\"Z!+O'"W M7'^ALM@DW[> '5*$0S79BD5IVYSJDMOCG+81CVR8)T+5A73-8B/?I4ACOI%J M1:.T+\ZH2JL72MD(1A*@PA7'?X;@WO5S>A18>FKM_-)6-U7A1#K&/F]4(FI1 M*FI<,CHI[8(M)2/GG?XT%FA;58^>)*5%#2GFMP)8VE8WK20Y[Z(F1ASKM]U9 MX.H8K$@UW(*/N#3+E;.XU#%8<2GMR"ORYA&8-YQ,76&!B,_O9%_*$=_VI*HD M;X6UM.MO>W+EO(L;=9)61^A;K7EQ_S5?]+2 %=Q2G:'YJA>W,4)I/$DQS]-: M#BM8I<)$[J1EG&9M3E_,^%BYK!B5"A:ETYD1I]:I8R[^U7)8\2F5,*J2QS&\ MM8%F;L=F;@>G5.*P@./,1WBL!VWF2->8VP;:::GR47T0-X:^AH=S5:M3-8,5 M)L-K ^GAW0A,\P,],S86'BL\I:)&XZYNQ6W$K%AYK#W3'^=3GPK.VH&PK.Y*_.SR><[/;RO>CH MV59=;B&AF^K?:?\.[AZ][GS-(O77W%"@T"[V4-RP5H&86])2ND$!E 1[65C" M?*:-GSBSK^:6CU9MW0(1[ _5'QA;;?TI#,@4#OZU7^;GR]9WZ.,O>4 #? M\C<8? 2? B8<6KH"H>XZC^@NFD^!JQ35B,AO4RTWE8^F\Y/IZ?SHE7O:QC8F MI/ZU,T'+M3;!?$=)P\:U@&SU^Q;MF2\O,37*ZT3T%S4^NS2?O_.G6?M9F>1; M5PO2NTP:-:[9Y8<633:XX:0)X%G)NTA0 O]!#K?Y^S>9TLV,CC947;34"(*$ M7WWJ"H*ZB"<.?K,U-B^Q-5XT&1BH0?>P:$M([PAHUJ]GEAQ9-5EZ^5-MHZ=:C&?8% M3W5T-2![T517 Y2.-P?%[,5559;8)-5WW@7Z] JT9MAK?O6I2^>'O /XV9NL MHO[7:CJ:T!Y^HPEM1X#A#J^N@Z^;WYG[P-[@MKJAL&1 ?"^8VL?+'/[WA?)_/(S"UXPXY<3.QOQ??G^Q_E$L%!N%N0=>6$?@QI.PF\)[6[B+)D($6;C8AA%T"D1NQP*_!.LD%/A"LNB%"71D+# MX5ZS$F"I=B]S6'7+>1C]NCARR4P:JAN4A[Y\=?L&R[%I_7&>WAEMMT+ MHW?D_B+CKQ&C\FUVS%1%_ +!FK2@WA7Q0Y5"1,Y8N8S.U;D!B:"D*W5O=N)7 M+&\GQ=[B&3.TP9#HKC!;KI5RO@R%KA!7>-==O+7;$0=7FM_L=C(]L'<5L@@? M:/D7Y(>@73V_"=@C9L_$30=F:ZFNL^XO'KGRC4,L999K6:Z4V\HE+?^"/@Z1 M#9F'.4FS[P0^X5=QX:M?C4:N51';3TEUQ^:9T#K>/CZ-KXH7[;=R]>](Y8%6 MR9E&G/T[=$L%-+_*N82_T<1S#C;]6*(_#ED+]N_EK MP/Z H76)]D0@/[ZZ+5G4*H@=(]S?E@E&J^X#=C%Y3I?H.@8K$$;;O](:?!5B M>8/[3L^QU[>RC0X59%[M;J87L1K]#RS0ZBB#W.CE(:!%"=)\FJ+V*MFO(-+?^,7LDNW$%/@VF< MN'$$?MKBZ]T*>Q[V+B"JR>0/^>F$NL'J!YK)KN6-2H:Y:WZ =-[%WB4D\ > M+7:J$$D2@!LR#W*27FX1#,M;FEF"-7"9()I;]-J)#+0$I..+G)VYG6KZK.^\ M-7K9 )MKQ#7T08ZSXB\8Y%^?0IE":@V]UTV:+EIC==D^IEPAOI ;^XUBO3BD M+'%@7[P@YEW_&1)QN 736!A=U2VVF#W!W(FF!O]9U0:N7_>PQ"?=\/;L%1I]*I/>WQ=9;GC>[ZPH&G1R766JHO1K; [HY+2O\+#?0:PFT^$JL\3G MGO2\02.U^_XVFQ85@]RAB5'F)6$/LU&9(^N;>'22G_^HC\N= 5W@><")Z?#0WX MAEG%*IT]1(?D:/&%O(]!K7EQA:+(GM#B4Y1LJ=)EME?'-G,%6+Z*:#(WZ M6Q]&JB/E) SDRSY[Z(8PL?.G?+<*P,;C0B+-? M9^*XDXP*,"^Y::KD3U/F?EV*-L:)D3_G]@95Q)Y1J'D!*WOF\86FI_DM909: MK[O"*Y%6-^Z"N/R5>%E#'ZA'ES[B/-G1+9GZ,^F%2H&%I^<,('^NM@ M3/V6 MQ7Q&G:$7[$8QI:])97IGI^B-C6E8+E6^2U9TJPGC(%R+:TUQQS^25X$Q!>M7 M^@].1U4K,[WS"U=>L(/-WE>R&08A-UW! )>G=E%AD%8_?0"SPY+ MBBO-+G$,R&Z+T8.R^%J5?VO&1Y%A$%9''?GT$EBZ.L,Q)+NWD)?:+,_R]&J[ MX1'JU/7\NR4T!I9JEWUY?E#MY,0C+LC\[."D9::0.QMYYK;WS0=A; MOB>UO*#4\/1J^](5 5B1+,X0?Y^V0<@A*ZU>TML(#<([&9I+1IH6HZ8"/8\W M5YEQ$X1,+O2-/&LC-(B5MW*Y'925=1GO4&9!FJ?495_#0M^2<0TFU](6R6E5 M:6Z6. QK81VJMC9#'(2UC^2UKO(P+%ME3:&^XC H>]5FL7XK.2A[9?&CMC(R M*&N?:L;"T]!&@E\[=//D05@,>8M?$\?RY%XM_B^B(6*')-'*9UXE#YJQ]^K1 M%\HR?W.@Y(&9W*O%GQ%SM]$HUAU;E2O;67NN[^1.>@RU'2.]5YOO@F=EQB-V M SF0&^Q8FHOTZMD-DF]^+]?W#'/BP?.2(Y46AW)5Q^*2]YZ;.^U[;XC;_D7:#/2.5 39:,3M*#]->8 M^;5QV:9@:%X_XKU0IJD]IRU#ZZI@L%[?D'54E>WN=[V*7CV/?BVG7^=)!VK1 M/0M?WQFL4OT8^$J.WU+7E+-6,O5JO>&RR9+Q-3Q#FS=Z;P #O&N\:*BB]Y-0 M_9>!]XSX:5B/7SF(@ONAHH[037P8M9TM8;5ON109!F&U/ERK/0D8GM71PE%S M(+#NR^:/L^CJWA__!U!+ P04 " !B>DY60#:Y1^<, !DE0 %0 '!H M8FDM,C R,C$R,S%?8V%L+GAM;-5=46_;.!)^/^#^ \_WL"EPCF.G[;9!LPLW M28L :1PDZ>Z^%8I$V[R52:](.E?W>X?G^]OT"7SXQFF EU$V!,X0,]$3)'ZZ9O'!8ZZW;3U;\M^SM#@ M^/3XY,/Z^\\>EU2,)C3RQ_[ZETO)#[$Q\A7GA/1DT.N?]@8G@]-UHP MA)$7^5,BL"_BR M1@#F94"0%1TN%SM#P)Q]=3KUHYLTC//.H4@H-%^)XS>N" MS5\C,ID*=.2_0:H;=-V]O7I$GV-.*.8T7!T3WF M.%K@(&47$OKGF?KC2>J'I*$I/WOAY+PS%6)^UNL]/S\?/Y\>LV@B]3GI]_[X M=O/@3Z5<74*5P7W<65$I+GET_8\?/_:27U=-,RU?GJ)PU<=I;R6.;,[)&4^Z MNV%^8EP &3*V4)^ZJV9=]56W/^B>]H]?>-"1UD!H:8^(A?@>CY'Z^_O]];K/ M^?2)'/MLUE,_]"Z8]$DI8T(RC?#XO*,:2+Z#07^PY/KOK4;B=2Y]DY/9/)3* M]?;HD0:82C^4_^ L)('RY"]$NHA/O/!!R(_*QWFY4-7X'$KN.SE J)AB07PO M;$J)7*96--KT.1J/YCA*')8/J6PTDV-Y*@G( M\PSK]3+P[D+!#LI62-?JSK M_2"8_^>4A8&<1B_QF/A$-*;5>PJQ-(G\)HIQ<$.\)Q(2 1"T"H^Z\MXPCZXZ*I,KKVT#8TM&0T$DRULF MRFUC:E]7CDLI* M] W/F&08Q+/1^#M5L5 M?.3T5B95*6$3WD)$$M16X6$B5VJO$-61)LZ'\.FT[R:<>H=5DSE<5=M#:)O.\:K*"*6W,CL 88?0 MVI2O7T? ?E,2FG+/JHA7Y=-@3EO=.4M)F\UYJPH(H[82NX!C!T)K4[[2L0,B MMI;#5P6\,B-;.?X^0ZD*GZ;7 %7EA=*;Y?2]T(_#)+>YD9^WVN,7@25ZZ[J? M$AFR[2"(4 U/EO_U47>ST:7]4VTO74D#BU=T3<O1HG/I?S)%M'8XT_)/E',NQ// MFZO-NT$/AX*OODF$?&$](L?0\[Q1I'0>$ATM6/M,'J]YX#V51%V2S9\M=M MN33\AY&/6"3GDO/.8,7$B_PMU+.;:VF+'H]G2__J$@G.BGXYGFG[\:HJVS_'OM8IE MH@4_>$8 ,8%XW3MK7F=6RS!95#!,8YZ83=;4-S^&P4*5E/@7J=0P#(GZ\#5B MSS)'OF#1/ ;WZ*R;BU6SXO+:.:C':+M1O7A@7 M>$MN8Y#3V"NVF(V>+;R8-&V/"VF[EB589%N"@+!7?P #8=+1=I%!Z_>:\]@P M,:JFN2U!YK5732@WKU'RMCGY, B(4M@+[SP27-,+;T[$YH&/G"J RJ'>0ZD45]1KV]P++?.KM&N9&?G9WKBS_:6_MD-GI_H?,T-$6]S>' M.T!7YXEO3?>W,-TUC=D8;?I+SA%N]8A4E^AHW>D;%^?P4@'I)#W^4E"WSVG: M9"F \CA4W+_@7"&6:^GM1FX/X1E-M[W\S].K/='M"XND '2YM>'KCQ!\E;FX M\M#/>"S;%"XM*S%Q>VBO%+1]5#*"VG6$ZE=,I9JA.D@4S @E7"S/6:=*FY$L M)71[C@^*'E#_]@S#NXB-,>=)0#-::;.IV@(1$;^SVT%J!_#M8F#%K3QA)RJER><.V MM2J-(F5T+G19K'-< ML& 6*"1R>^1N+[0 1FC/?*W.J>/$GC-5&OD[,8J4F?#EB7;I[=KC [=80*+U3C/'!_]RA3:%Z)R6>]<[+9Z8 M ^D$\]36.-=&H>VBZ[*86!2^B^D<'ZR#J;6#73Z^K8%J2[QZNYY[L')\Z*T^ MH#4W%5SE;#FG+\IT)/F48A'\-UYF M).5HV^K/\?F_ZHYBU_"MW6FL_!9B;=?MW3Z[;GHG/Z&TFZV=-B>;CP5O*M8T M?K^/QHHU2GB[WE!4KSF0PMQ%;$&DW3Z_?I>B7]-U+CV4/KTH>4*H"@]7U7HB MBI<[>ANW^Y35$:,V.F+D"[3I_)R7XA4!6L8/[<;MA;0KV+&5OM#E=LUJHS]8GYN-U@MS@;P M2TK:.?'G/&Y?!?U<[ UZ)T>VZZU1L_EX6B-[F,<)&_QTE9& MZ@!$X:+=3.1XC[DZ:-EE?)E%VN.BNK";%#KGFIQB$ VD[C>?FX.RT#KM!%1_ M:3U\0&:IW.^W-P>CR2;M0?!>IK6O:2D;CF QE>-M^-H(0FS2HAQ?*:O^5X^U M+;P0)VM4+B+B2\'5#S(YW?Y":WF'(\*";,J3/AMW]>)//3K!]]((5^,Q]HO> M/'E@.1P?#G!C]NQA@ZK)[OZ'G"QNS[?8ED7S1FNF\:5BH[&N[(C6,NO:@)>$ MSQGWPJ\1B^?JN+':G$CNI\)!]H[3[+S0!ME;3__ M9W69B-0Q9%QRD1^6[-2N_?K*^>6SP6N6VT\.6SFL +OB5U/CPZX:&@>T88$V M/"Q(7:F4I@G_<5?X%2.45JP)FXDX&O$F8J;D-O W762LR9@)+!LB MM*(Z=/0NB.*#3&@IB>+H:/4O.V:/#:29ZFU<.!_3^\EN=-15R%I&;U<7!A ;>]*S) MG0G2.RN0@XD.N@):$QP>J:V.5]C%T)KM 5O]DFA-BTRH+5AP'73( M5KH]6E,H$W/-B[+##0GH[=*:'ID G%FXF<5/Z\[JCR?IBK_\#U!+ P04 M" !B>DY6/0PO@BP; >H@$ %0 '!H8FDM,C R,C$R,S%?9&5F+GAM;.U= MW7/;.))_OZK['WB^A\U6G>/(3C*3U&:WY*\I;R66RW9F]FV*)B$)MQ3I@*1M MW5]_ $E(((DOBH0@.-J'V=CN!KI_C<]F=^-O_WA91-X30"E,XB\'H[?O#CP0 M!TD(X]F7@SP]]-, P@,OS?PX]*,D!E\.EB ]^,??__,__O9?AX?_.KW]ZITG M0;X <>:=(>!G(/2>83;WR)^^^6D&T.%A1?U[V<]G[_CMR=MWOZY^?^JGF"N) M"Q[\Q]'J+^>X/2^9>@%IN6!]=WPT.CDZ?G=\LB*Z2Z;9LX^ YZ-@#C,09#GR M(R\$*9S%'A;<*Q7Z[(W_$GCG,2P=D\\]X$ M?_5(-][5X?7%O7>:IS &:>K=)5%.1$G_Q[N*@[?>.(J\6\*1>K<@!>@)A%5S M$8S__9G\YP'KYV&@X_3S2PJ_',RS[/'ST='S\_/;YY.W"9IA?=Z-CO[U[>M= M,,=R'<*8 !Z \I%6N'QC3Y]^G14_)62MBA?'E!$^S@YHN*L6L9_#;,5 TO\ MX:C\(R9-X>>TD.QK$A1VT.C!$U*0GPXIV2'YU>'H^/!D]/8E#0\P<)Y70H>2 M"-R"J4?^__OMU:K/Q_D#?!LDBR/RAZ.S! ]?+&/!,D=@^N6 $.!VCX]'QV6K M_UTCRI:/>!BG^SG(5XPPHV4[-&/<;WOLB3X]SR)0KSBGH,I#& VG+(ZC1O7\,Q/YY=1 M\CR@$<5-]M7FVL=;$IA,Z292#)(X@W%.5GEV^*B4Z-Y27]GO\"8*L9'].!L' M09*3SF8W&+\ J6X6LQ]):Q:QDO,TG^( (8$_P;E(/P*_0<8P4Q#T"YM])7W M:^+'M".57#S: >86W@TSB)N\3C(U-B+ZOG*< P2?\&#%BZ2^H:1,?26Z!1%9 M%/!>E2WO$4;>#[1FI8JOO\46BR0NUEVUL5JD?7N_P5T!A,ABJ2$ G[KW*H1/ M[> FQP=\?&;\PT<89/4!2\K45Z)O8)'@!L-\,9E^C\E>2.Y(>'E32:5D'&*T MP*S8U.CV,,.7NJ7.T)'Q];9A_I""'SEN_^))YWPLHC>ZHPVRL]G8X>[)7P;9 MY^HM&5GE]8358#6RKNA)I\&ZO7/C.X;IBK\,[]!FOJXRZ_$96!TVSZ_":E&_41\#14!**SIY=+=ZUG0'/M-T' MIY)UV#-O5P'UN(WL79IS1X?7I'S*N:/%;.P,W]7@G1LR=<;?9"IU:6?H.T!7 M>77YQ7+Z**"B\DC9[@5?,.B'$?+IXD,AU1PW@8+\ 1R&<$'\ODE\X%4=L5BL M6H%Q=H1)CRJ:(VX#IJ5>=748)@L?=A2YS6U91L/1LK.2HQ_"6-(CC-?\8\UJ<%+!O"" MO7+UD^9TOC1F,".$[\K_C;S#]6?P0Z^@]&[\&?"NXFF"%L55JORV266*DJ F M2$0^K2:HC5]*%4]!\':6/!V% )(/X,?D'\7J6"((X)]%O^.'-$/X\$9;BOP' M$!7M_XEI*B4J=(XX\!C K>-W3@;:8XSFBJ) MFK+8QOS5JUY;',FAD"?KYV, M7B>;Z^6]J;7^UZWIV>>#)Z/Z>SW5&863J;?NKPCHJ/7HD2Z]-ZM.[2"B]564 M@>'#)C"PG?S%J[JIJ=YSC9GZZ4.QPN;IX DJ>*4H6 M2MRJ_A*IP G"8^7+ =YHWV&.8M?]'.!C/A[Z%U%!B'=N,"/_6/\]2O X_'*0 MH;RE\I;-<_$CA]F23/X)7&;,V^$2&Y.NRLJL= S6$ M.J^N "+#",A-&J1]/U%90S;6&L81Z%,9Y<1AH_PY:@EOS"[TJ&[:,(5.E6W> M:RR#-FS'^#2_5;=4D=TXI$8-5K\["XPE'7L-(W$4H,O9R [Z=8>MR@!\:K=L MP->!FN%X(S.TW77D-^S0ODK3G.QY0H0)@X3>$8P56E"43^P,]G$8%J#YT8T/ MPZOXS'^$F1^I1KV"S1'3Z"E#+?3>DH6"(%_DQ?>X";[GH]IU]RK&EU+Q#*(* MZC?AF.7T%:-6_&#'BK?DVT0,P@L?Q3">I2J3B>C=LH]("VJ,CW:,<9W$Y+R' ME<:MSJ[PR0^!-%.91,[EEF'DNE#S_&+IPD\^]Z9DHUQ[RSCW^QJ5??CUO3(U MP2NL+9UU61]B.7[PJAGE81&_B H LPS!ASPC9Y;[A#]N9$Z88=IWR;P#J4PG MH<6!48[1\QP1V0&"25B.W6OP7/Q)ZGW3XW?-L!HJ49V:[*[ M;[:F1M0E9,=JHM,K^9IUF2 9_%9CF_H<<#&XXWCL/@I*KZ&CH+!QKLEIQV'[-55MF[+0AKVJIP+]JRZLU M-KP2W'3QM;"C=TUA"P9OQ6$D;HJ?/,Y(-6I*Q3!Y%=?PDLDSR1GQCIOBK3E- MVU.96,Z(>=(4LV+V"FZOSF["T.W$'D$>.B/2AZ9(*Q9S M4LE3TAGA/K:61,+I459OS3N\D.H,=4;0U@ZTYB8[38/?S+B39JTSLK;V&89Y MO4U6[ :,+TIH9T1L;2=K)H]R;7G'ENSV_HOXP4:>U# MNENY]Z9LU(A..EGPC!*:NY51D752XQF16SN78*TS*O, &?&,2JWMKNNYW'M3 M=>.M^K$V8YIYH8R>K3U4?\I4K1K12BO%GE&CM=O6SL5<6^P#[?>!]J\HT/XL M\E.:Q:(99-]F<3/ OJV'Y>!Z5B!5$#>/=K?"ZD4CJQD4S%'$3VUVUY,"VC2#6@WX,=M (N[!D#64(=L7ZN*-)/W?S!&7W "W. MP4-VCSM2G+SXY&ZL7'(=&$/MA"%4V[V083?.7K)QI3)(8QW[Q7&3[,*:-IQ9 MV%7M5S.KFB"@HOX])9W$\B0N,;G]( GQN9X-DA!K0!>KS0*X15ER8WE2W'@' M\),??-H0KH6FD V:6,AZ^8ZEZ'$I[0]$Q1K'0LG5@**Z6=RQ!JHC;51'SJ,Z M:J*Z65RP!%7J8W]$,+I_QK-H>?^<5/^8)WGJQ^&R_%$)>_>FG+-+=Q6IX2S% MX6*!J\"TJFQ3/#M+TDQRH!=S[("U=!WA8B7LYCDQ041DP)6!W9*\)1&]0Z80 MJ= KKTBPH)WG@+S.-IF2 "W!2M6@<0%)CMB]DGL$Z-T6[=/,KTG\/7[T87CJ M1]6S;SPT%3RNH*M0HU=2C@#MJY@\()B"L-ZW &+^X3)E07@I1D M^*H.' HVARRBT*29/K)=Z]#EKQHLRG.@B-XA>XA4J SQR5!UIS+!ZQ8$ #YQ MRS@TZB(UZ5U 6*$"O?+8BEC@[TU:EYXZ@PNV4.E C6'I BI-,.%L!WQRAPPA MT(":P5)9B]MDZ4?9\N+ED63]B?%OTCD$?%-TBOB@5]9+'Z(B0W0R#=JY/HU5 M7D3L J@R^2FREFI&X(V&U.]?WF4DPX9DQDK]BP)R%XP@UX":8=";++E27&*= M\/I%XO//01H@^)@Q(0\<1[R(P06,53I0E"U=:-DKGO+4SB5VP0@R^:D!!JV, M0'HJ#ZPR/TV+R@4LN8)3$"U=/^\ O@>#4.L3!(_6!=PEXE/T-[MS#AM%1*_% MQ"U*?:2:\41\5I=LH];&AXREHTZK8OK6BK+H M/0S+9->U4L1;]1WV&7;[#+M7FF$W?O912#XGRV.[&V1.Q70W9+>\CZRD404, MMPAW(G:;.UY$@.](HMRFD.]0;/8&L+OPK,S7))YEV@DF?&JGUB*^"B82XWI8 M035-1/0[L4#)AI3"&"93Y+9NCAU:O'J;9 O)<@)OU#_]./?1E[#X-4W[L33.4%]6_UH/K%,08WP#ZT7KT78*B1JG,E)NTYI19-U'0;MK/ M/LVU^4E\T&BI#[(>%RPC88:)M)^?KKT[PU3>O;YWTUX]?*_-TS: MV03N\13_^KS\Q"(=SYU;>14FX2G6+Z5'Z#%_@8M\@<5 ,$YA4!VK[^?@ NL8 MAB#L=FHM_="]VG3%@#W5[)"58$'>I[OV0Y7#*(B(EC"0=W8(P#T!XYB.TQ"?H:N(VW$"B_4B/UP7P.ZAC M.2NI/CZ^QW[Y70&$]'."[OS@LKI@*WUMC.0OE8>5.[+3S4#Q]::J0"8]M7'I M74!;H8+E[";! X7X"D4NHK6B(!(?<;=67+#:1HI9SI5BREI@@2:HT+)\%/@& MH*+2A=R^D,&IT'VA%I83BHJ->PH0>1+R#J G M2#YUK*K=LN*F)%POY?])%60^;"\[D2F@&,<-\P\+@.6,*/?&S ZE,]@;-UM( MZ1(&2;6"1Z3QM!)Z^Z=L$Z._'CXE5+Z5%K_M>A/X8G!*:N_B"P2)J?-+Y#$@ MLV+PG"[7)-4EO@@W7L41C=,T7Q2182F)R@O(K2/!M\1"2^((D!S7MM&Y_='5 MH>;%%O"P&S0\J(JW,/WW)0* +0^RI='&[_IG'6M\-.R&1!N93+2ZB85UK=[U MSSK2^&CTB@(?9J0]J!5\Z*(@*7W$JW7&@FJH3]?&EB$8FH'LV_&5"CSP.G6+ M3MXU/9!58U[1FLZ#46*P'?$5]C/,#OGM#!C'6HTEU8OKJB?*&R^NB\G=6.[D.IB8 M0%MZ\M[VNC;4<_=F:EQMR0B[L(8-90AVQ?JP0RO6#0(IN>)GPL\*F*I%9/_N M*MX=&6NTY*8KTOZ)[JY/=)\,FM-QZ9/'VB93]>@K7]T04+LP#*4*4' '?I&E MT1OS1KT>O@R#LQ S.E"4!RU\1#QA?KP\PPLX5B8"Z'1Y-H=@_0E^E 4=XL14(;94S><;VIL;B+-*L% MQ7IWWAY5EH"0\=@W2I]71UO/C@PY :ZJ%TT#@)>[%%\B8#R[!,*R16)R%S"6 M:V#B07E%U$$ID&O1 6VI[7Y;)16_T<#^Z^/^Z^,K_?KXTSZ?8NL)Z9_X^1377JS9!;?YYK"SCO*3K<;: M3X(LP8>*LE3S) :M\LTJ/UJ7!NR?D33*67=1R$B!)BH N5EWKBVNR^R4*53* M&"G!= Z"HOG+)$<9(+7[.YJB2P-.F*.+0I;+*/%+ )Y)WVJO>#58[5NK9RW$ M,]X[[K;N'%@((AD(SW-2U.,&()B$16AM6O[^,D%EYA37O[1"I%L[#MFPJVJ6 MDR/XTA81T?WM*6K&?7.*--N!!(1JD-T@+)&Z_(F$Q24KB;6PXR2[P08%"(%0 MVT]VW/23K9K8N\KVKK)7[2I;:7$6^6E*ZH7A\2YWFTE8G'*A2?2P[$YC!5*Y M=WBT.^%44XZL9O$LCB*6?6S][+!#GK;^MK#G>,,'/ C2\5V.I__O"?F<7-_@ MI:X%76;[YRWQ6&,]"[KZ]/.W#>!58(4J3XCC/)LGB-3ZE+D4Y'SVS=3!GR!7 MQ:XSH2Y=]\J-NOS.&DQ=O]%ZO4W]:25E\ESZ M,+KM3I3'(>O(U+#[\EQ=LF*\Z%JC(G;6#)7\O9Z%$QR@F_ZP%,YB,A\%1V8Q MN0O@RC5H/O:V'8=D,<5NRAV3FNQ..2DU=;+L**M+>>TOE%%I M8HZ=<%YV&HE2D[&J6:X9,IR5=LBU:<)2]BKZTJU=ZM1L$MD_EZE&%GLZ:TKO M:O'=BQ\YS)9,Z>$)R?B[G_OQI"QE=TT 2?&Y\SH7&)/]@KX=$>P/%?,E*[NC M8B+QSYSXOQ73Y^+E$2+A)6YKO;LPH+8*B(DLQS\ G,WQ>!WC!=:?@8L7?,:$ M*2BB;4[!#,:Q^$%Q35Y7[*BI3B_GX@96D,]&+<[78('F+!BT8H.TXSC<; I0 MQE>!?J5+TXEHW\O%>ZOKY'U7-]?^L:Z]HVOOZ-H[NBQ&YNT=75T<7>Z[(W\B M1]=VH_KHYGX'7TB&G):_JT%K_\BVB=NKH821Q-A57^ )FTT;WB:UHP WU3"2 M]$I[N\;G%6V$F\1N MS4HE\&JP)?O=QZ(;6;" O3YX?U9]1ZZX#O:P"WB>RP MGHJJJXOBKJZY.#2)W42WJ07%=]"(IKHI5>4%A-1N(BRL(+!9,4D]B)55.R7T M3L/,J=HY^M4$T+I;G/.;&V=;^V1FY.HN"\XO",VE8,-[MPI0_47@%4Q_SL3? M,$1! 2LI$J.%*DOH)JBL!A13([>R2_BD-U)90D'VTGE]N@LAI0 M3,U-7*(N(NTUM4[J)JQU'2BRAFY3(-(\4]5)W42VKD._ MN'WEM0HB;2=AD]A1=!M:&'EXC;UT:./;)'83WZ861EYI6U] IOKPUFD=1;>N MA)%7VLK(],F4]GE$4"61V@?5KU81I[L)D+QF_UH0NDND&:BT&NQI@(,&S2N M -@0NU,O5J[>UK@.ZCD5]I-/)IGF(]TW0<_,AA"M7QQT(&IR*.A5I8 MCE[ER47^B8 RC%6#=2>BCA4C3L-0#:TL9]:;--D.A2 /;#9[:?;?)M^E]U7F M[_:/8MJ#BSV9,1I83K"G^5R3APC.BJQ;\63@T=HW@'Y)+X[X=NM\,F/F+$FY M5]^*M$WI$/!MX9L7X.V]SPFS(DU\'(?D@7,X W&PU+F,?.0]UEDUYN$[B+=N M;G\7V=]%7NE=Y";R"S>L_ )2IW+JUE$7W?)5@PJC.J0VZ7;B$L$;*@*P=^2: ML!G<.W0!Z SY%H[XO:UR"R)2'?3&1]GR'OEQZ@=%89?3)?L7^8+4I0VGEJLN MBEF>7:Q JAG&H]V)1:W[8)08K+'LO7?2,#NT_!DP#KM ?MCF IFBC+$=_FEM M-_S#^IC\&TAFR'^0N['#&YW75- M#FS;"&(]F%GBFA%V80T;RA#LBO5QJU[;,[S48M5@/!O/$"CZ^>:33,C.+TYO MU))]?QC__L"Z?3=2C*YN@P;=B"2I^A[&7JK&7#:92C=JM4%C?#C"W(''K.BR MR#6@8FQH-:W&'+6:EF[4:H/&%LF$J:(5A[*;O#G7+2?7CMINT&RPLKXL_7*T M7@)D!E+PN& %A0H4ZD$SQ*Z3I^*CW%T2Y<6][2H.I#C+&.R#++Y6UV)#)3I0 ME =-&!M'$?3C /R&DF> TK,$/4I!EM"[@K%$!0KQH/EC9V/Y^CW> 0#E=SG. MLCQN0C9HAAAGU<L[ FEV*XY0EW(XBG!="1-I$XT. MKY,,!FS93CVP.6R.(L[1Q$2^Q7H-NP1 E/+3)'(%TJ;<)IX[6"W]C*E$. IH M78%3(+Z)1PQN$'CT87CQ0MX@ 21*[!P$BG,4NFVIF9S!6NU)KW>0.W]L?)K M$L_N 5J0S-!+'R+%*[0"L(=>@^53J,&MRX_WN\MGA]6IV!] 3WAS$R[4V MOPL&Z*A299&!KT7<[F4#7R*U8Q- 3Y,*]D%O-+7]6^=LXA*@-;$MO]<@,*]X M/1;[AUZ#($<@+&HNY @![FF'*LNA=<@$//&-U*'_YK_ 11Z7 M=J;N]")Q>76H%:PO6IPN0*ZMC)%"];2SHG2 ^EHO)G<%:K$&1JK4C\.P@,&/ MUODP>&=1(ZW#Z KF.KH8J61?G3Y7DPAW>N,O20"=V@":O*[80%,=(P7OQ^$3 M^;Z47F+1.1^;A#- P>4*]$I%^I7 'R"G#!^URD/6>8[PT?<&()B$Q05B75V* M%"B!LA3,CLVX8+W--#-2:+]\KG?Y?)*MKZ.S7A@H&Z:]4JN["E9WCSAQ3\R+$N%^0=M%0G]?R7 MUDN\JT:\LA5NQGFA5Z45^<\#OA7\_?\!4$L#!!0 ( &)Z3E:]V<7G"40 M /]V P 5 <&AB:2TR,#(R,3(S,5]L86(N>&UL[7W[<]PXDN;O%W'_ ZYW M(Z8[0G;7^]&W,QNR9/=ISRWI;+EG[SHN)E D*/&Z1-:0+-G:O_[PX!L/@JPB M@-[='V;:JLI$?2 ^ HE$(O.?_OG;\QZ\H"0-X^C/WTW?3KX#*/)B/XP>__S= M,7T#4R\,OP-I!B,?[N,(_?F[5Y1^]\]_^:__Y9_^VYLW__KNTT=P'7O'9Q1E MX"I!,$,^^!IF3X!\]0M,,Y2\>9-+_\I^YR
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�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end

1.	We have reviewed this quarterly report on Form 10-Q of Pharmagreen Biotech Inc. for the quarter ended December 31, 2022;

2.	Based on our knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on our knowledge, the financial statements, and other financial information included in report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.	We are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

February 14, 2023

By:	/s/ Peter Wojcik
	Peter Wojcik
	President and Director
	Principal Executive Officer

By:	/s/ Terry Kwan
	Terry Kwan
	Principal Accounting Officer

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects the financial condition and results of operations of the Company.